Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Endoscopic examination, therapy or surgery of the luminal surface of the colon.
A benign epithelial tumor with a glandular organization.
Discrete tissue masses that protrude into the lumen of the COLON. These POLYPS are connected to the wall of the colon either by a stalk, pedunculus, or by a broad base.
Radiography using air, oxygen, or some other gas as a contrast medium.
A malignant epithelial tumor with a glandular organization.
The distal segment of the LARGE INTESTINE, between the SIGMOID COLON and the ANAL CANAL.
Tumors or cancer of the RECTUM.
Lining of the INTESTINES, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. In the SMALL INTESTINE, the mucosa is characterized by a series of folds and abundance of absorptive cells (ENTEROCYTES) with MICROVILLI.
Tumors or cancer of the COLON.
The segment of LARGE INTESTINE between the CECUM and the RECTUM. It includes the ASCENDING COLON; the TRANSVERSE COLON; the DESCENDING COLON; and the SIGMOID COLON.
Methods to identify and characterize cancer in the early stages of disease and predict tumor behavior.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A group of autosomal-dominant inherited diseases in which COLON CANCER arises in discrete adenomas. Unlike FAMILIAL POLYPOSIS COLI with hundreds of polyps, hereditary nonpolyposis colorectal neoplasms occur much later, in the fourth and fifth decades. HNPCC has been associated with germline mutations in mismatch repair (MMR) genes. It has been subdivided into Lynch syndrome I or site-specific colonic cancer, and LYNCH SYNDROME II which includes extracolonic cancer.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.
A surgical specialty concerned with the diagnosis and treatment of disorders and abnormalities of the COLON; RECTUM; and ANAL CANAL.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Tumors or cancer of the LIVER.
Neoplasms containing cyst-like formations or producing mucin or serum.
Endoscopic examination, therapy or surgery of the sigmoid flexure.
DNA present in neoplastic tissue.
Benign neoplasms derived from glandular epithelium. (From Stedman, 25th ed)
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tumors or cancer of the SKIN.
Discrete abnormal tissue masses that protrude into the lumen of the INTESTINE. A polyp is attached to the intestinal wall either by a stalk, pedunculus, or by a broad base.
A polyposis syndrome due to an autosomal dominant mutation of the APC genes (GENES, APC) on CHROMOSOME 5. The syndrome is characterized by the development of hundreds of ADENOMATOUS POLYPS in the COLON and RECTUM of affected individuals by early adulthood.
Organic compounds which contain platinum as an integral part of the molecule.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Tumors or cancer of the LUNG.
Organized periodic procedures performed on large groups of people for the purpose of detecting disease.
A variety of simple repeat sequences that are distributed throughout the GENOME. They are characterized by a short repeat unit of 2-8 basepairs that is repeated up to 100 times. They are also known as short tandem repeats (STRs).
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Tumors or cancers of the KIDNEY.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
MutS homolog 2 protein is found throughout eukaryotes and is a homolog of the MUTS DNA MISMATCH-BINDING PROTEIN. It plays an essential role in meiotic RECOMBINATION and DNA REPAIR of mismatched NUCLEOTIDES.
Human colonic ADENOCARCINOMA cells that are able to express differentiation features characteristic of mature intestinal cells such as the GOBLET CELLS.
Excision of a portion of the colon or of the whole colon. (Dorland, 28th ed)
Tumor suppressor genes located in the 5q21 region on the long arm of human chromosome 5. The mutation of these genes is associated with familial adenomatous polyposis (ADENOMATOUS POLYPOSIS COLI) and GARDNER SYNDROME, as well as some sporadic colorectal cancers.
A cell line derived from cultured tumor cells.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Tumors or cancer of the THYROID GLAND.
Tumors or cancer of the INTESTINES.
Human COLORECTAL CARCINOMA cell line.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Pathological developments in the RECTUM region of the large intestine (INTESTINE, LARGE).
Family of retrovirus-associated DNA sequences (ras) originally isolated from Harvey (H-ras, Ha-ras, rasH) and Kirsten (K-ras, Ki-ras, rasK) murine sarcoma viruses. Ras genes are widely conserved among animal species and sequences corresponding to both H-ras and K-ras genes have been detected in human, avian, murine, and non-vertebrate genomes. The closely related N-ras gene has been detected in human neuroblastoma and sarcoma cell lines. All genes of the family have a similar exon-intron structure and each encodes a p21 protein.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Addition of methyl groups to DNA. DNA methyltransferases (DNA methylases) perform this reaction using S-ADENOSYLMETHIONINE as the methyl group donor.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Tumors or cancer of the APPENDIX.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A raf kinase subclass found at high levels in neuronal tissue. The B-raf Kinases are MAP kinase kinase kinases that have specificity for MAP KINASE KINASE 1 and MAP KINASE KINASE 2.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Tumors or cancer of the PAROTID GLAND.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A multi-functional catenin that participates in CELL ADHESION and nuclear signaling. Beta catenin binds CADHERINS and helps link their cytoplasmic tails to the ACTIN in the CYTOSKELETON via ALPHA CATENIN. It also serves as a transcriptional co-activator and downstream component of WNT PROTEIN-mediated SIGNAL TRANSDUCTION PATHWAYS.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
A DNA repair pathway involved in correction of errors introduced during DNA replication when an incorrect base, which cannot form hydrogen bonds with the corresponding base in the parent strand, is incorporated into the daughter strand. Excinucleases recognize the BASE PAIR MISMATCH and cause a segment of polynucleotide chain to be excised from the daughter strand, thereby removing the mismatched base. (from Oxford Dictionary of Biochemistry and Molecular Biology, 2001)
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Biochemical identification of mutational changes in a nucleotide sequence.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Small, monomeric GTP-binding proteins encoded by ras genes (GENES, RAS). The protooncogene-derived protein, PROTO-ONCOGENE PROTEIN P21(RAS), plays a role in normal cellular growth, differentiation and development. The oncogene-derived protein (ONCOGENE PROTEIN P21(RAS)) can play a role in aberrant cellular regulation during neoplastic cell transformation (CELL TRANSFORMATION, NEOPLASTIC). This enzyme was formerly listed as EC 3.6.1.47.
Any detectable and heritable alteration in the lineage of germ cells. Mutations in these cells (i.e., "generative" cells ancestral to the gametes) are transmitted to progeny while those in somatic cells are not.
Tumors or cancer of the SIGMOID COLON.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Pathological processes in the COLON region of the large intestine (INTESTINE, LARGE).
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Tumors or cancer of the ENDOCRINE GLANDS.
Tumors or cancer of the STOMACH.
Elements of limited time intervals, contributing to particular results or situations.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
A negative regulator of beta-catenin signaling which is mutant in ADENOMATOUS POLYPOSIS COLI and GARDNER SYNDROME.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Tumors or cancer of the EYE.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
Tumors or cancer of the NOSE.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Antibodies produced by a single clone of cells.
Antimetabolites that are useful in cancer chemotherapy.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Excision of all or part of the liver. (Dorland, 28th ed)
A non-invasive imaging method that uses computed tomographic data combined with specialized imaging software to examine the colon.
Tumors or cancer of the SALIVARY GLANDS.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
A broad category of carrier proteins that play a role in SIGNAL TRANSDUCTION. They generally contain several modular domains, each of which having its own binding activity, and act by forming complexes with other intracellular-signaling molecules. Signal-transducing adaptor proteins lack enzyme activity, however their activity can be modulated by other signal-transducing enzymes
Tumors or cancer of the human BREAST.
Tumors or cancer of the UTERUS.
Tumors or cancer of the PERITONEUM.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
The presence of an uncomplimentary base in double-stranded DNA caused by spontaneous deamination of cytosine or adenine, mismatching during homologous recombination, or errors in DNA replication. Multiple, sequential base pair mismatches lead to formation of heteroduplex DNA; (NUCLEIC ACID HETERODUPLEXES).
Tumors or cancer of the DUODENUM.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
A general term for various neoplastic diseases of the lymphoid tissue.

Transformation mediated by RhoA requires activity of ROCK kinases. (1/13490)

BACKGROUND: The Ras-related GTPase RhoA controls signalling processes required for cytoskeletal reorganisation, transcriptional regulation, and transformation. The ability of RhoA mutants to transform cells correlates not with transcription but with their ability to bind ROCK-I, an effector kinase involved in cytoskeletal reorganisation. We used a recently developed specific ROCK inhibitor, Y-27632, and ROCK truncation mutants to investigate the role of ROCK kinases in transcriptional activation and transformation. RESULTS: In NIH3T3 cells, Y-27632 did not prevent the activation of serum response factor, transcription of c-fos or cell cycle re-entry following serum stimulation. Repeated treatment of NIH3T3 cells with Y-27632, however, substantially disrupted their actin fibre network but did not affect their growth rate. Y-27632 blocked focus formation by RhoA and its guanine-nucleotide exchange factors Dbl and mNET1. It did not affect the growth rate of cells transformed by Dbl and mNET1, but restored normal growth control at confluence and prevented their growth in soft agar. Y-27632 also significantly inhibited focus formation by Ras, but had no effect on the establishment or maintenance of transformation by Src. Furthermore, it significantly inhibited anchorage-independent growth of two out of four colorectal tumour cell lines. Consistent with these data, a truncated ROCK derivative exhibited weak ability to cooperate with activated Raf in focus formation assays. CONCLUSIONS: ROCK signalling is required for both the establishment and maintenance of transformation by constitutive activation of RhoA, and contributes to the Ras-transformed phenotype. These observations provide a potential explanation for the requirement for Rho in Ras-mediated transformation. Moreover, the inhibition of ROCK kinases may be of therapeutic use.  (+info)

Expression of Bcl-2 protein is decreased in colorectal adenocarcinomas with microsatellite instability. (2/13490)

Bcl-2 is known to inhibit apoptosis and is thought to play a role in colorectal tumour development. Studies of the promoter region of bcl-2 have indicated the presence of a p53 responsive element which downregulates bcl-2 expression. Since p53 is commonly mutated in colorectal cancers, but rarely in those tumours showing microsatellite instability (MSI), the aim of this study was to examine the relationship of bcl-2 protein expression to MSI, as well as to other clinicopathological and molecular variables, in colorectal adenocarcinomas. Expression of bcl-2 was analysed by immunohistochemistry in 71 colorectal cancers which had been previously assigned to three classes depending upon their levels of MSI. MSI-high tumours demonstrated instability in three or more of six microsatellite markers tested, MSI-low tumours in one or two of six, and MSI-null in none of six. Bcl-2 expression in tumours was quantified independently by two pathologists and assigned to one of five categories, with respect to the number of cells which showed positive staining: 0, up to 5%; 1, 6-25%; 2, 26-50%; 3, 51-75%; and 4, > or =76%. Bcl-2 negative tumours were defined as those with a score of 0. Bcl-2 protein expression was tested for association with clinicopathological stage, differentiation level, tumour site, age, sex, survival, evidence of p53 inactivation and MSI level. A significant association was found between bcl-2 expression and patient survival (P = 0.012, Gehan Wilcoxon test). Further, a significant reciprocal relationship was found between bcl-2 expression and the presence of MSI (P = 0.012, Wilcoxon rank sum test). We conclude that bcl-2 expressing colorectal cancers are more likely to be MSI-null, and to be associated with improved patient survival.  (+info)

99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. (3/13490)

Vasoactive intestinal peptide (VIP) is a naturally occurring 28-amino acid peptide with a wide range of biological activities. Recent reports suggest that VIP receptors are expressed on a variety of malignant tumor cells and that the receptor density is higher than for somatostatin. Our aims were to label VIP with 99mTc--a generator-produced, inexpensive radionuclide that possesses ideal characteristics for scintigraphic imaging--and to evaluate 99mTc-VIP for bioactivity and its ability to detect experimental tumors. METHODS: VIP28 was modified at the carboxy terminus by the addition of four amino acids that provided an N4 configuration for a strong chelation of 99mTc. To eliminate steric hindrance, 4-aminobutyric acid (Aba) was used as a spacer. VIP28 was labeled with 1251, which served as a control. Biological activity of the modified VIP28 agonist (TP3654) was examined in vitro using a cell-binding assay and an opossum internal anal sphincter (IAS) smooth muscle relaxivity assay. Tissue distribution studies were performed at 4 and 24 h after injection, and receptor-blocking assays were also performed in nude mice bearing human colorectal cancer LS174T. Blood clearance was examined in normal Sprague-Dawley rats. RESULTS: The yield of 99mTc-TP3654 was quantitative, and the yields of 125I-VIP and 1251-TP3654 were >90%. All in vitro data strongly suggested that the biological activity of 99mTc-TP3654 agonist was equivalent to that of VIP28. As the time after injection increased, radioactivity in all tissues decreased, except in the receptor-enriched tumor (P = 0.84) and in the lungs (P = 0.78). The tumor uptake (0.23 percentage injected dose per gram of tissue [%ID/g]) was several-fold higher than 125I-VIP (0.06 %ID/g) at 24 h after injection in the similar system. In mice treated with unlabeled VIP or TP3654, the uptake of 99mTc-TP3654 decreased in all VIP receptor-rich tissues except the kidneys. The blood clearance was biphasic; the alpha half-time was 5 min and the beta half-time was approximately 120 min. CONCLUSION: VIP28 was modified and successfully labeled with 99mTc. The results of all in vitro examinations indicated that the biological activity of TP3654 was equivalent to that of native VIP28 and tumor binding was receptor specific.  (+info)

Genomic structure and alterations of homeobox gene CDX2 in colorectal carcinomas. (4/13490)

Expression of CDX2, a caudal-related homeobox gene, was found to be decreased in colorectal carcinomas. Heterozygous null mutant mice as to Cdx2 develop multiple intestinal adenomatous polyps. To clarify the role of CDX2 in colorectal carcinogenesis, we determined its genomic structure, and searched for mutations of CDX2 in 49 sporadic colorectal carcinomas and ten hereditary non-polyposis colorectal cancers (HNPCC) without microsatellite instability. None of them exhibited a mutation. We further examined 19 HNPCC carcinomas with microsatellite instability for mutations in a (G)7 repeat site within CDX2. One of them (5.3%) exhibited one G insertion. Loss of heterozygosity was observed in 2 of the 20 (10%) informative sporadic carcinomas, and in one of the three (33.3%) informative HNPCC cancers. These data indicate that CDX2 may play only a minor role in colorectal carcinogenesis.  (+info)

Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. (5/13490)

Marimastat is a specific inhibitor of matrix metalloproteinases that has been shown to be effective in cancer models. A pilot, escalating-dose study of oral marimastat was performed in patients with recurrent colorectal cancer, in whom evaluation of serological response was made by measurement of carcinoembryonic antigen (CEA) levels. The study assessed the safety and tolerability of 4 weeks administration of marimastat, and determined a dose range producing detectable serological effects. Patients were recruited with a serum CEA level greater than 5 ng ml(-1), and rising by more than 25% over a 4-week screening period. Patients were treated for 28 days and entered into a continuation protocol if a serological response or clinical benefit was observed. Pharmacokinetic and safety data determined that groups of patients were recruited sequentially at 25 mg and 50 mg twice daily, and, thereafter, 10 mg twice daily, 10 mg once daily, 5 mg once daily and 20 mg once daily. A biological effect (BE) was defined as a CEA value on day 28 no greater than on day 0; a partial biological effect (PBE) was defined as a rise in CEA over the 28-day treatment period of less than 25%. Of 70 patients recruited, 63 completed the 28-day treatment period, and 55 were eligible for cancer antigen analysis. Examination of the dose-effect relationships provides evidence for a causal relationship between marimastat and biological effects: the proportion of patients with BE or PBE was higher with twice daily dosing (16 out of 25, 64%) than with once daily dosing (11 out of 30, 37%) (P = 0.043, chi2 test). Furthermore, the median rates of rise of CEA fell markedly during treatment compared with the screening period for patients receiving twice daily marimastat (P<0.0001), but not for patients receiving marimastat once daily (P = 0.25). Musculoskeletal adverse events emerged as the principal drug-related toxicity of marimastat, occurring in a dose- and time-dependent fashion. It was concluded that marimastat was associated with dose-dependent biological effects in cancer patients. The occurrence of musculoskeletal side-effects define 25 mg twice daily as the upper limit of the dose range for continuous use in further studies. Therefore, a dose range of 20 mg once daily to 25 mg twice daily seems appropriate for further studies, which should aim to demonstrate the efficacy of the drug in terms of conventional clinical end points and describe the long-term tolerability of this novel agent.  (+info)

Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers. (6/13490)

The conflicting results about the prognostic impact of tumour cell proliferation in colorectal cancer might be explained by the heterogeneity observed within these tumours. We have investigated whether a systematic spatial heterogeneity exists between different compartments, and whether the presence of such a systematic heterogeneity has any impact on survival. Fifty-six Dukes' stage B colorectal cancers were carefully morphometrically quantified with respect to the immunohistochemical expression of the proliferative marker Ki-67 at both the luminal border and the invasive margin. The proliferative activity was significantly higher at the luminal border compared with the invasive margin (P<0.001), although the two compartments were also significantly correlated with each other. Tumours with low proliferation at the invasive margin had a significantly poorer prognosis both in univariate (P = 0.014) and in multivariate survival analyses (P = 0.042). We conclude that Dukes' B colorectal cancers exhibit a systematic spatial heterogeneity with respect to proliferation, and tumours with low proliferation at the invasive margin had a poor prognosis. The present data independently confirm recent results from the authors, and provide new insights into the understanding of tumour cell proliferation in colorectal cancer.  (+info)

Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. (7/13490)

Dihydropyrimidine dehydrogenase (DPD) is responsible for the breakdown of the widely used antineoplastic agent 5-fluorouracil (5FU), thereby limiting the efficacy of the therapy. To identify patients suffering from a complete or partial DPD deficiency, the activity of DPD is usually determined in peripheral blood mononuclear cells (PBM cells). In this study, we demonstrated that the highest activity of DPD was found in monocytes followed by that of lymphocytes, granulocytes and platelets, whereas no significant activity of DPD could be detected in erythrocytes. The activity of DPD in PBM cells proved to be intermediate compared with the DPD activity observed in monocytes and lymphocytes. The mean percentage of monocytes in the PBM cells obtained from cancer patients proved to be significantly higher than that observed in PBM cells obtained from healthy volunteers. Moreover, a profound positive correlation was observed between the DPD activity of PBM cells and the percentage of monocytes, thus introducing a large inter- and intrapatient variability in the activity of DPD and hindering the detection of patients with a partial DPD deficiency.  (+info)

Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study. (8/13490)

To estimate the efficacy of screening on colorectal cancer mortality, a population-based case-control study was conducted in well-defined areas of Burgundy (France). Screening by faecal occult blood test prior to diagnosis in cases born between 1914 and 1943 and who died of colorectal cancer diagnosed in 1988-94 was compared with screening in controls matched with the case for age, sex and place of residence. Cases were less likely to have been screened than controls, with an odds ratio (OR) of 0.67 [95% confidence interval (CI) 0.48-0.94]. The negative overall association did not differ by gender or by anatomical location. The odds ratio of death from colorectal cancer was 0.64 (95% CI 0.46-0.91) for those screened within 3 years of case diagnosis compared with those not screened. It was 1.14 (95% CI 0.50-2.63) for those screened more than 3 years before case diagnosis. There was a negative association between the risk of death from colorectal cancer and the number of participations in the screening campaigns. The inverse association between screening for faecal occult blood and fatal colorectal cancer suggests that screening can reduce colorectal cancer mortality. This report further supports recommendations for population-based mass screening with faecal occult blood test.  (+info)

This is a phase II study to assess whether treatment with chemotherapy drugs FOLFOX (5-Fluorouracil (5FU), Oxaliplatin (Eloxatin) and Leucovorin (Folinic Acid)) or FOLFIRI (5-Fluorouracil (5FU), Irinotecan (Camptosar) and Leucovorin (Folinic Acid))and panitumumab before and after surgery can improve outcome in patients with liver metastases (the cancer has spread to other parts of the body such as the liver) that are resectable (can be surgically removed), from colorectal cancer that have a non mutant (wild-type) K-ras gene.. FOLFOX/FOLFIRI is an intravenous (given by vein) chemotherapy combination that is approved for colorectal cancer while panitumumab is also an intravenous drug and have been approved for treatment of refractory (not responding treatment) metastatic colorectal cancer whose cancers have the K-ras gene. These drugs are not approved for the treatment of colorectal cancer liver metastases (CRCLM) who can have surgery.. Patients will receive FOLFOX/FOLFIRI and panitumumab for four ...
Dysregulation of microRNAs has been confirmed to serve an important role in cancer development and progression. However, the role of microRNA (miR)‑544 in colorectal cancer progression remains unknown. In the present study, it was observed that the expression level of miR‑544 was increased in breast cancer cell lines and tissues using the quantitative polymerase chain reaction. Overexpression of miR‑544 promoted cell proliferation and invasion in colorectal cancer, whereas inhibition of miR‑544 suppressed colorectal cancer progression as determined using MTT, colony formation and Transwell assays. Furthermore, forkhead box O1 (FOXO1) was a direct target of miR‑544. FOXO1 mediated miR‑544‑regulated colorectal cancer progression and cell cycle distribution. In conclusion, the results of the present study revealed that miR‑544 serves an important role in promoting human colorectal cancer cell progression ...
Whether to perform primary tumor resection in patients with asymptomatic Stage IV colorectal cancer remains controversial; however, the more aggressively we perform radical resection and metastasectomy to selected patients, the more survival benefits the patients obtain.
PubMed journal article: Prognostic significance of the lymph node ratio in stage IV colorectal cancer patients who have undergone curative resection. Download Prime PubMed App to iPhone, iPad, or Android
We established an in vivo model of organ-specific colorectal cancer metastasis and demonstrated that the CD110+ tumor initiating cells contribute for colorectal liver metastasis. To gain a deeper understanding of its metastatic capacity, we performed a genome-wide transcriptome analysis on the CD110+ tumor cells derived from primary colon xenografts and their matched liver metastases. Results provide important information of the responses of the CD110+ cells during the process of liver colonization. Total RNA obtained from the CD110+ cells sorted from primary colorectal tumors (CRC102-PT and CRC108-PT) compared to those from the corresponding liver metastases (CRC102-LM and CRC108-LM).
Fingerprint Dive into the research topics of Clinicopathological Factors Associated with Recurrence and Prognosis after R0 Resection for Stage IV Colorectal Cancer with Peritoneal Metastasis. Together they form a unique fingerprint. ...
BACKGROUND: Identification of high-risk stage II colorectal cancer (CRC) patients, potential candidates for adjuvant chemotherapy, is challenging. Current clinical guidelines rely mainly on histopathological markers with relatively weak prognostic value. This motivates further search for prognostic markers.. METHODS: This explorative study aimed to identify potential candidate gene mutations to facilitate differentiation between subgroups of patients with CRC stage II. Panel-based massive parallel sequencing was used to genetically characterize tumor tissues from 85 patients radically operated for CRC stage II, of which 12 developed recurrent cancer during follow-up. Genetic data was compared between patients with or without cancer recurrence, between tumors located in colon and in rectum, and for association with tumor differentiation grade.. RESULTS: Genetic variation in ATM, C11ORF65 was associated with recurrence-free survival. Previous reports regarding the association between BRAF mutation ...
TY - JOUR. T1 - IGFBP-3 gene methylation in primary tumor predicts recurrence of stage II colorectal cancers. AU - Fu, Tao. AU - Pappou, Emmanouil P.. AU - Guzzetta, Angela A.. AU - De Freitas Calmon, Marilia. AU - Sun, Lifeng. AU - Herrera, Alexander. AU - Li, Fan. AU - Wolfgang, Christopher L.. AU - Baylin, Stephen B.. AU - Iacobuzio-Donahue, Christine A.. AU - Tong, Weidong. AU - Ahuja, Nita. N1 - Funding Information: Supported by the National Institutes of Health (Grant Nos. CA140599 and CA127141); the Society of University Surgeons Award, Jeannik M. Littlefield-American Association of Cancer Research grant in metastatic colon cancer (Grant No. K23 CA127141); and the National Natural Science Foundation of China (Grant Nos. 81000898 and 81472289). We thank Kathy Bender and Joann Murphy for administrative support. We also thank Sharon Metzger-Gaud, Theresa Sanlorenzo-Caswell, and the Johns Hopkins Cancer Registry for assistance with the primary cancer databases.. PY - 2016. Y1 - 2016. N2 - ...
The U.S. Food and Drug Administration (FDA) has approved panitumumab (Vectibix) for use in combination with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as first-line treatment in patients with wild-type KRAS (exon 2) metastatic colorectal cancer.. This approval converts the accelerated monotherapy approval granted in 2006 to a full approval. Panitumumab was previously approved by the FDA as a monotherapy for patients with EGFR-expressing metastatic colorectal cancer after disease progression and prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy. The agent is not indicated for the treatment of patients with KRAS-mutant metastatic colorectal cancer or for whom KRAS mutation status is unknown.. The FDA has also approved the therascreen KRAS test as a companion diagnostic to guide use of panitumumab in the treatment of metastatic colorectal cancer.. Phase III Studies. The approval is based on results from the phase III PRIME and -ASPECCT trials. The ...
Although disease stage is the most relevant factor influencing treatment choice in locally advanced radically resected colorectal cancer, it is not uncommon to observe disease relapse in patients with apparent low risk stage that are usually excluded from an adjuvant therapy. On the contrary we also know that some patients with high risk stage are not likely to relapse independently from medical treatment received. Preclinical data suggested that cancer stem cells may influence the biological behaviour of many solid tumours including colorectal cancer. We tested a panel of genetic markers of stemness in resected Dukes stage B and C colorectal cancer and their impact on prognosis. We performed k-means unsupervised clustering (K = 2) using the mRNA expression data of 66 genes. The algorithm divided the patients into two groups (A and B) and most of the patients clustered in a manner consistent with relapse free survival, defined as the time between primary surgery and first radiological sign of ...
TY - JOUR. T1 - Systematic review of internet patient information on colorectal cancer surgery. AU - Wasserman, M.. AU - Baxter, N. N.. AU - Rosen, B.. AU - Burnstein, M.. AU - Halverson, A. L.. PY - 2014/1. Y1 - 2014/1. N2 - Patients diagnosed with colorectal cancer often seek information on the Internet to help them make treatment decisions. OBJECTIVE: The aim of this study is to evaluate the quality of Web-based patient information regarding surgery for colorectal cancer. DESIGN: This study is a cross-sectional survey of patientdirected Web sites. SETTINGS: The search engine Google (Mountain View, CA) and the search terms colorectal cancer surgery, colon cancer surgery, and rectal cancer surgery were used to identify Web sites. MAIN OUTCOME MEASURES: To assess quality, we used the DISCERN instrument, a validated questionnaire developed to analyze written consumer health information on treatment options to aid consumers in evaluating the quality of health-related information on treatment ...
Metastatic Colorectal Cancer - Pipeline Review, H1 2014SummaryGlobal Markets Directs, Metastatic Colorectal Cancer - Pipeline Review, H1 2014, provides an overview of the Metastatic Colorectal Cancers therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics
Background Oxaliplatin is effective in adjuvant and first-line colorectal cancer chemotherapy. Oxaliplatin-induced severe chronic neurotoxicity is the main dose-limiting adverse event. No standard treatment for oxaliplatin-induced chronic neurotoxicity has been identified.. Materials and methods We conducted a prospective pilot clinical trial to explore whether neurotropin has neuroprotective effects on chronic neurotoxicity. From May 1 2010 to July 1 2011, 80 stage II and III colorectal cancer patients who were eligible to receive oxaliplatin-based chemotherapy voluntarily enrolled in the trial. The patients were randomly divided into 2 groups, one of which received neurotropin treatment.. Results The patients in the control group experienced significantly ≥ grade 2 and ≥ grade 3 neurotoxicity (by NCI CTCAE grading) than did those in the neurotropin group (60.9% vs. 38%, for at least grade 2 neurotoxicity, P = 0.001; 39% vs. 2.7%, for at least grade 3 neurotoxicity, P < 0.001). If ...
MedStar Montgomery Medical Center offers a wide array of advanced colorectal cancer treatments for both complex and common colorectal cancer types.
Overview. Colorectal cancer (CRC) is a common malignant tumor developed in the gastrointestinal tract. The incidence and mortality of colorectal cancer are on the rise, and most patients are diagnosed in the middle and late stage. Globally, the incidence of colorectal cancer ranks third among the incidence of all cancers, and colorectal cancer mortality ranks fourth among cancer-caused deaths.. Colorectal cancer gene detection is detection of colorectal cancer-related genes in samples of cancer tissue and peripheral blood through use of high-throughput sequencing platform. Through colorectal cancer gene detection, detection of genes associated with colorectal cancer and conventional chemotherapy for colorectal cancer and personalized medication guidance for patients can be achieved.. The Necessity of Genetic Testing. KRAS genes will affect the efficacy of cetuximab and panitumumab. The effective rate of first-line treatment of wild-type KRAS gene colorectal cancer with cetuximab or Pani ...
Colorectal cancer (CRC) is a heterogeneous and biologically poorly understood disease. To tailor CRC treatment, it is essential to first model this heterogeneity by defining subtypes of patients with homogeneous biological and clinical characteristics and second match these subtypes to cell lines for which extensive pharmacological data is available, thus linking targeted therapies to patients most likely to respond to treatment. We applied a new unsupervised, iterative approach to stratify CRC tumor samples into subtypes based on genome-wide mRNA expression data. By applying this stratification to several CRC cell line panels and integrating pharmacological response data, we generated hypotheses regarding the targeted treatment of different subtypes. In agreement with earlier studies, the two dominant CRC subtypes are highly correlated with a gene expression signature of epithelial-mesenchymal-transition (EMT). Notably, further dividing these two subtypes using iNMF (iterative Non-negative Matrix
TY - JOUR. T1 - The prevalent KRAS exon 2 c.35 G,A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?. AU - Russo, Antonio. AU - Tessitore, Alessandra. AU - Bruera, Gemma. AU - Cannita, Katia. AU - Ricevuto, Enrico. AU - Ficorella, Corrado. AU - Alesse, Edoardo. PY - 2015. Y1 - 2015. N2 - Bevacizumab-containing chemotherapy differently predict increased efficacy in KRAS exon 2 mutant and wild-type metastatic colorectal cancer (MCRC) patients. Mutant compared to wild-type status did not significantly affect progression-free survival (PFS) and overall survival (OS) in patients fit for first line bevacizumab-containing FIr-B/FOx regimen, and after progression. In patients unfit for intensive regimens, mutant status significantly affected PFS, while not OS. Codon 12 KRAS mutations differentially affect GTPase function, and confer worse clinical behaviour. Prognostic relevance of the prevalent c.35 G. ...
Physical activity is consistently associated with a reduced risk of colorectal cancer in epidemiologic studies. This association among higher risk subgroups, such as those with a first-degree family history of colorectal cancer or high body mass index remains unclear. We searched MEDLINE for studies examining physical activity and colorectal cancer risk among higher risk subgroups through July 11, 2017. Fifteen and three studies were eligible for inclusion for body mass index and first-degree family history of colorectal cancer subgroups, respectively. Estimates of the highest to lowest comparison of physical activity for each subgroup of risk were pooled using random-effects models. The pooled associations of physical activity and colorectal cancer risk for those without and with a first-degree family history of colorectal cancer were 0.56 (95% confidence interval (CI) = 0.39-0.80) and 0.72 (95% CI = 0.39-1.32), respectively (pheterogeneity = 0.586). The pooled associations of physical activity and
Metastatic Colorectal Cancer Pipeline Review, H2 2012 Global Markets Directs, \Metastatic Colorectal Cancer Pipeline Review, H2 2012\, provides an overview of the Metastatic Colorectal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Colorectal Cancer, complete with latest updates, and special features on late-stage and discontinued p
FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping. Yeh, Yung-Sung; Huang, Meng-Lin; Chang, Se-Fen; Chen, Chin-Fan; Hu, Huang-Ming; Wang, Jaw-Yuan // Medical Principles & Practice;Sep2014, Vol. 23 Issue 5, p478 Objective: To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping. Clinical Presentation and Intervention: A... ...
OBJECTIVES: To assess the prior exposure to colorectal examinations between colorectal cancer (CRC) patients and matched control participants to estimate the effect of these examinations on the development of CRC and to obtain insight into the background incidence of colorectal examinations. METHODS: A population-based case-control study was conducted within the Dutch Integrated Primary Care Information database over the period 1996-2005. All incident CRC cases were matched with up to 18 controls (n=7,790) for age, sex, index date (date of CRC diagnosis) and follow-up before diagnosis. All colorectal examinations performed in symptomatic participants in the period 0.5-5 years before index date were considered in the analyses. RESULTS: Within the source population of 457 024 persons, we identified 594 incident cases of CRC. In the period 0.5-5 years before index date 2.9% (17 of 594) of the CRC cases had undergone colorectal examinations, compared with 4.4% (346 of 7790) in the control population ...
Colorectal Cancer Development Pathway from normal colorectal epithelium to cancer Colorectal cancer develops via an adenoma to carcinoma sequence with the accumulation of a number of genetic and epigenetic mutations (Figure 1‑3) (Morson 1968; Fearon and Vogelstein 1990). The mutations accumulated vary in hereditary cancer depending on the initiating mutation. In their normal…
Colorectal cancer stem cell (CSC) has been regarded to be the root of colorectal cancer progression. However, there is still no effective therapeutic method targeting colorectal CSC in clinical application. Here, we investigated the effects of dichloroacetate (DCA) on colorectal cancer cell stemness. We showed that DCA could reduce colorectal cancer cell stemness in a dose-dependent manner, which is evident by the decreased expression of stemness markers, tumor cell sphere-formation and ...
Significant variability has been reported in the rates of proliferation of colorectal cancer tumors, and faster proliferation is associated with poor patient prognosis (9-12). In primary colorectal tumors, an association has been reported between high-grade (poorly differentiated; refs. 24, 25) or MSI (26) and faster proliferation rates. Here, we show that cell lines that form high-grade tumors when grown as xenografts or have microsatellite instability proliferate significantly faster than cell lines forming low-grade (differentiated) tumors or MSS lines. These results indicate that the proliferative profile of the cell line panel used here closely recapitulates the characteristics of primary colorectal tumors. This is consistent with our recent findings demonstrating that the mutational landscape of colorectal cancer cell lines closely resembles that of primary colorectal cancers (27), and collectively establish cell lines as suitable models for the investigation of this disease. ...
TY - JOUR. T1 - Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II study. AU - Porta, C.. AU - Danova, M.. AU - Accurso, S.. AU - Tinelli, C.. AU - Girino, M.. AU - Riccardi, A.. AU - Palmeri, S.. PY - 2001. Y1 - 2001. N2 - Purpose: Several trials have suggested that intrahepatic chemotherapy increases the likelihood of response in advanced colon cancer patients, but has no significant impact on survival due to the development of extrahepatic metastases. We report our experience of combined hepatic intraarterial and systemic chemotherapy in advanced colorectal cancer patients. Methods: A group of 35 patients received intrahepatic FUDR (0.3 mg/kg per day for 14 days by continuous infusion), followed, after 1 weeks rest, by systemic 5-FU and L-leucovorin (370 and 100 mg/m2 per day, respectively, both for 5 consecutive days). After another week off therapy, the combined intrahepatic and systemic regimen was ...
Results An optimal 13-gene expression classifier (PIGR, CXCL13, MMP3, TUBA1B, SESN1, AZGP1, KLK6, EPHA7, SEMA3A, DSC3, CXCL10, ENPP3, BNIP3) for prediction of relapse among patients with stage II CRC was developed using a consecutive Norwegian test series from patients treated according to current standard protocols (n=44, p,0.001, HR=18.2), and its predictive value was successfully validated for patients with stage II CRC in a second Norwegian CRC series collected two decades previously (n=52, p=0.02, HR=3.6). Further validation of the classifier was obtained in a recent external dataset of patients with stage II CRC from other populations (n=108, p=0.001, HR=6.5). Multivariate Cox regression analyses, including all three sample series and various clinicopathological variables, confirmed the independent prognostic value of the classifier (p≤0.004). The classifier was shown to be specific to stage II CRC and does not provide prognostic stratification of patients with stage III CRC. ...
Colorectal Cancer Drugs Manufacturing, Colorectal Cancer Drugs Industry, Colorectal Cancer Drugs Trends, Colorectal Cancer Drugs prospects, Colorectal Cancer Drugs Growth , Colorectal Cancer Drugs Segmentation, Colorectal Cancer Drugs Sharing, Colorectal Cancer Drugs Enterprise, Colorectal Cancer Drugs Application, Colorectal Cancer Drugs Analysis,
In a study reported in the Journal of the National Cancer Institute, Imperiale et al found that the National Cancer Institute (NCI) colorectal cancer risk assessment tool was able to estimate the current risk for advanced colorectal neoplasia.. Study Details. The study involved 4,457 persons aged 50 to 80 years undergoing first-time screening colonoscopy. The NCI tool was used to calculate the future risk of colorectal cancer on the basis of medical and family histories, lifestyle information, and physical measures. Advanced neoplasia was defined as a sessile serrated polyp or tubular adenoma ≥ 1 cm, a polyp with villous histology or high-grade dysplasia, or colorectal cancer. Subjects had a mean age of 57 years, and 52% were women.. Correlation of Risk. The overall prevalence of advanced neoplasia was 8.26%. Based on quintiles of increasing 5-year estimated absolute colorectal cancer risk, current risks of advanced neoplasia were 2.1%, 4.8%, 6.4%, 10.0%, and 17.6% (P , .001). For quintiles of ...
Etiology of the colorectal cancer is not completely understood. It is not possible to definitely clarify why some people catch the disease and why others do not. What we do know is colorectal cancer is not contagious. This disease is not transmitted from one person to the other.. Age: Risk of being caught by the colorectal cancer increases by aging. Ninety percent of people with final diagnosis of colorectal cancer are older than 50 years. Mean age at diagnosis is around 60 years.. Colorectal polyp: Polyps outgrow on interior wall of the colon. They are common in people older than 50. Polyps are mostly benign in nature or they do not transform into cancer. However, some polyps (i.e. adenomas) may progress into cancer. Diagnosis and excision of polyps substantially reduce the risk of colorectal cancer.. Familial history of colorectal cancer: Colorectal cancer is more likely for people who have a family member (parents, siblings or children) with personal history of colorectal cancer. The risk is ...
TY - JOUR. T1 - Changes of KRAS Exon 2 Codon 12/13 Mutation Status in Recurrent Colorectal Cancer. AU - Dócs, Ottó. AU - Fazakas, Ferenc. AU - Horváth, Nóra Lugosiné. AU - Tóth, L.. AU - András, C.. AU - Horváth, Z.. AU - Méhes, G.. PY - 2014/9/24. Y1 - 2014/9/24. N2 - Colorectal cancer (CRC) is a heterogeneous disease presenting with a wide spectrum of morphological and molecular characteristics sometimes even within the same patient. To understand the mechanisms of oscillations in the KRAS status we evaluated the collective of CRC patients tested using allele-specific PCR and Sanger-sequencing. Mutant KRAS allele was observed in 43.3 % of cases. Repeated analysis of KRAS status in recurrent tumors or metastases was performed in 18/665 cases and a total of 6 cases with different KRAS status was found. In three cases the histological pattern of the tumor was identical. In one patient different histology and molecular status was seen between the primary and the recurrent tumor samples. ...
Researchers from the University of Hawaiʻi Cancer Center and Office of Public Health Studies have found that patients who have type 2 diabetes in addition to other chronic diseases have a lower survival rate for colorectal cancer.. The study. Type 2 diabetes and colorectal cancer survival: The multiethnic cohort, published in the International Journal of Cancer, investigated the survival rates of colorectal cancer patients with or without type 2 diabetes, and with additional diseases such as heart disease or stroke. The findings showed type 2 diabetes alone does not significantly affect survival for colorectal cancer patients. However, patients with type 2 diabetes as well as other chronic diseases had a lower survival rate.. The researchers looked at 24 years of health data of more than 215,000 adults from California and Hawaiʻi who participated in the multi-ethnic cohort to identify predictors of survival. Among 3,913 new cases of colorectal cancer, the 707 participants with type 2 ...
In this study, modest correlations of AREG and EREG relative mRNA expression were observed between primary colorectal cancer and corresponding liver metastases. We have previously reported the correlation of VEGF [14], EGFR [15], and 5-FU metabolism-related genes [16] between primary colorectal tumor and liver metastases. Although EGFR mRNA expression showed a relatively strong correlation between the primary tumor and metastases [15], the correlations of AREG and EREG, which are the ligands of the EGFR family, between primary and metastases were weaker than that. The median values of AREG and EREG expression did not differ between primary cancer and metastases, which suggested that there was no up-regulation in the liver metastases. The strength of correlation was similar between synchronous and metachronous metastases, which suggested that expression levels were well preserved, even in relapse, for long time after primary tumor resection. Interestingly, the significance of EREG as a prognostic ...
We established an in vivo model of organ-specific colorectal cancer metastasis and demonstrated that the CD110+ tumor initiating cells contribute for colorectal liver metastasis. To gain a deeper understanding of its metastatic capacity, we performed a genome-wide transcriptome analysis on the CD110+ tumor cells derived from primary colon xenografts and their matched liver metastases. Results provide important information of the responses of the CD110+ cells during the process of liver colonization.
Your age. Getting older is a risk factor for colorectal cancer.. Your race and ethnicity. African Americans have a higher risk of getting colorectal cancer (and dying from it) than people of other races. And Ashkenazi Jews (Jewish people whose ancestors came from Eastern Europe) who have inherited certain genes are also at a higher risk for getting colorectal cancer.. Your familys medical history. You are more likely to get colorectal cancer if one of your parents, brothers, sisters, or children has had the disease. Your risk is higher if this family member had colorectal cancer younger than 45 years old, or if more than one family member had the disease.. Some common gene changes increase the chance of colorectal cancer. These changes are familial adenomatous polyposis (FAP) and Lynch syndrome, also called hereditary nonpolyposis colorectal cancer (HNPCC). Many people with these changed genes will get colorectal cancer if they arent carefully watched. Genetic testing can tell you if you carry ...
TY - JOUR. T1 - Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. AU - Cremolini, C. AU - Antoniotti, C. AU - Lonardi, S. AU - Bergamo, F. AU - Cortesi, E. AU - Tomasello, G. AU - Moretto, R. AU - Ronzoni, M. AU - Racca, P. AU - Loupakis, F. AU - Zaniboni, A. AU - Tonini, G. AU - Buonadonna, A. AU - Marmorino, F. AU - Allegrini, G. AU - Granetto, C. AU - Masi, G. AU - Zagonel, V. AU - Sensi, E. AU - Fontanini, G. AU - Boni, L. AU - Falcone, A. PY - 2018/4/20. Y1 - 2018/4/20. N2 - Background: Right-sided metastatic colorectal cancer (mCRC) patients have poor prognosis and achieve limited benefit from first-line doublets plus a targeted agent. In this unplanned analysis of the TRIBE study, we investigated the prognostic and predictive impact of primary tumor sidedness in mCRC patients and the differential impact of the intensification of the chemotherapy in subgroups defined ...
TY - JOUR. T1 - Genetic epidemiology of colorectal cancer. AU - Petersen, Gloria M. PY - 1995. Y1 - 1995. N2 - Genetic epidemiological methods have played an integral role in the characterisation of the genetic susceptibilities to colorectal cancer. Classic epidemiological approaches, such as case-control and prospective cohort studies, that utilise family history information have laid the foundation for the more specialised family-based genetic methods, segregation analysis and linkage analysis. The genetic epidemiology of colorectal cancer can be characterised by several themes: the consistently increased risk of colorectal cancer in first-degree relatives of patients with colorectal cancer; genetic predisposition to some, if not the majority of colorectal neoplasms; and genetic heterogeneity of the inherited colorectal cancer syndromes. With the rapid development of molecular genetic techniques, new opportunities for further research include studies to estimate the proportion of colorectal ...
OBJECTIVES:. I. Compare overall survival in patients with locally advanced, metastatic, or recurrent colorectal cancer treated with fluorouracil, leucovorin calcium, oxaliplatin, and bevacizumab vs capecitabine, oxaliplatin, and bevacizumab.. II. Compare progression-free survival and time to treatment failure in patients treated with these regimens.. III. Compare the response of patients with measurable disease treated with these regimens.. IV.Compare toxicity rates of these regimens in these patients. V. Compare patient-reported functional status and convenience of therapy in patients treated with these regimens.. VI. Correlate germline polymorphisms of DNA repair (e.g., ERCC-1, XRCC1, GST-P1, XPD, and ribonucleotide reductase), target enzymes (e.g., thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase), angiogenesis (e.g., vascular endothelial growth factor), and growth factors (e.g., epithelial growth factor receptor) with survival, progression-free survival, and ...
TY - JOUR. T1 - Cetuximab for the first-line treatment of metastatic colorectal cancer.. AU - Meads, C.. AU - Round, J.. AU - Tubeuf, S.. AU - Moore, D. AU - Pennant, M.. AU - Bayliss, S.. PY - 2010/5. Y1 - 2010/5. N2 - This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of cetuximab for the first-line treatment of metastatic colorectal cancer (mCRC), in accordance with the licensed indication, based upon the manufacturers submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process. The ERG project ran between 22 January 2008 and 4 November 2008. The clinical evidence came from two unpublished randomised controlled trials (RCTs) of cetuximab plus chemotherapy versus chemotherapy alone in the first-line treatment of mCRC. A third RCT submitted later compared cetuximab with irinotecan in combination with 5-fluorouracil (5-FU) and folinic acid (FA) and ...
1]. Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L. Role of oxaliplatin in the treatment of colorectal cancer. Ther Clin Risk Manag. 2009;5(1):229-38.. [2]. Hsu HH, Chen MC, Baskaran R, Lin YM, Day CH, Lin YJ, Tu CC, Vijaya Padma V, Kuo WW, Huang CY. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. J Cell Physiol. 2018 Jul;233(7):5458-5467. doi: 10.1002/jcp.26406. Epub 2018 Jan 23... [3]. Mohammadian M, Zeynali S, Azarbaijani AF, Khadem Ansari MH, Kheradmand F. Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines. Res Pharm Sci. 2017;12(6):517-525. [4]. Sonowal H, Pal PB, Wen JJ, Awasthi S, Ramana KV, Srivastava SK. Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity. Sci Rep. 2017;7(1):3182. Published 2017 Jun 9. doi:10.1038/s41598-017-03284-w. ...
The purpose of this study is to determine the activity of SCH 717454 in patients with relapsed or recurrent colorectal cancer.
At present, a full understanding of the mechanisms by which colorectal cancer (CRC) distant metastases form is still beyond our reach because of the intricate regulation of gene expression. MicroRNAs (miRNAs) are shown to be involved in various human diseases including cancers through negative regulation of target gene expression at the post-transcriptional level. However, there are only a few studies on the roles of miRNA aberrations in liver metastasis of human colorectal cancer. To identify miRNA expression patterns associated with liver metastasis in human colorectal cancer, the miRNA expression profiles of colorectal cancer tissues with liver metastasis and their non-metastatic counterparts were studied using microRNA microarrays and further confirmed by quantitative RT-PCR. We show that 28 miRNAs are differentially expressed in the colorectal carcinomas with liver metastasis compared to the non-metastatic counterparts. Of these, 4 miRNAs including miR-150*, miR-125b-2*, miR-1179 and ...
The liver is the most common anatomical site for hematogenous metastases from colorectal cancer. Therefore effective treatment of liver metastases is one of the most challenging elements in the management of colorectal cancer. However, there is rare available clinical consensus or guideline only focusing on colorectal liver metastases. After six rounds of discussion by 195 clinical experts of the Shanghai International Consensus Expert Group on Colorectal Liver Metastases (SINCE) from 29 countries or regions, the Shanghai Consensus has been finally completed, based on current research and expert experience. The consensus emphasized the principle of multidisciplinary team, provided detailed diagnosis approaches, and guided precise local and systemic treatments. This Shanghai Consensus might be of great significance to standardized diagnosis and treatment of colorectal liver metastases all over the world.
Colorectal cancer causes significant morbidity and mortality in the United States. The incidence of colorectal cancer can be reduced with increasing efforts directed at mass screening of average-risk adults 50 years and older. Currently, fecal occult blood test and flexible sigmoidoscopy have the highest levels of evidence to support their use for colorectal cancer screening. Colonoscopy does not have a proven colorectal cancer mortality benefit, but it does have the greatest single-test accuracy, and it is the final test in the pathway to evaluate and treat patients with other abnormal screening tests. Double-contrast barium enema has sparse data of effectiveness. Computed tomographic colonography, fecal DNA testing, and Pillcam Colon are promising tests that need further study before they can be recommended for widespread screening. Routine screening should continue until 75 years of age. There is good evidence that fiber and antioxidants are not effective for primary prevention of colorectal cancer;
Genetic markers associated with colorectal cancer may be used in population screening for the early identification of patients at elevated risk of disease. We genotyped 3059 individuals with no cancer family history for eight markers previously associated with colorectal cancer. After colonoscopy, the genetic profile of cases with advanced colorectal neoplasia (213) was compared with the rest (2846). rs2066847 and rs6983267 were significantly associated with the risk of advanced colorectal neoplasia but with limited effect on their own [odds ratio (OR) 1.59; 95% confidence interval (CI) 1.02-2.41; p=0.033 and OR 1.45; 95% CI 1.02-2.12; p=0.044, respectively]. Cumulative effects, in contrast, were associated with high risk: the combination of rs2066847, rs6983267, rs4779584, rs3802842 and rs4939827 minimized the number of markers considered, while maximizing the relative size of the carrier group and the risk associated to it, for example, for at least two cumulated risk markers, OR is 2.57 (95% ...
Genetic markers associated with colorectal cancer may be used in population screening for the early identification of patients at elevated risk of disease. We genotyped 3059 individuals with no cancer family history for eight markers previously associated with colorectal cancer. After colonoscopy, the genetic profile of cases with advanced colorectal neoplasia (213) was compared with the rest (2846). rs2066847 and rs6983267 were significantly associated with the risk of advanced colorectal neoplasia but with limited effect on their own [odds ratio (OR) 1.59; 95% confidence interval (CI) 1.02-2.41; p=0.033 and OR 1.45; 95% CI 1.02-2.12; p=0.044, respectively]. Cumulative effects, in contrast, were associated with high risk: the combination of rs2066847, rs6983267, rs4779584, rs3802842 and rs4939827 minimized the number of markers considered, while maximizing the relative size of the carrier group and the risk associated to it, for example, for at least two cumulated risk markers, OR is 2.57 (95% ...
Colorectal cancer is one of the deadliest malignancies with a grim prognosis and accounted for an estimated 55,000 deaths in the United States alone in 1998 (16) . A similar trend of increasing incidence and poor outcome have been reported in Japan also (17) . Among the several new treatment strategies to treat these patients, NSAIDs have drawn much attention in recent years. NSAIDs exhibited a significant antitumor effect in animal models (18 , 19) and colorectal polyps in humans (20 , 21) . Although the exact mechanism of this antitumor effect is not clear, it has been postulated that this effect could be partially attributable to the antiangiogenic effect through modulation of COX-2 activity (19) . Results from several experimental models indicate that COX-2 expression is associated with augmentation of neovascularization (11) . However, to date, it is not clear whether a similar correlation exists in the clinical setting in colorectal carcinoma patients. This is the first report showing ...
|i|Background|/i|: C-Myc, a well-known oncogene located on 8q24.12–q24.23, is often amplified and over-expressed in both primary and metastasizing colorectal cancer. In addition, PRL-3 (also known as PTP4A3), a tyrosine phosphatase located on 8q24.3, is amplified in colorectal cancer metastasis. Beside PRL-3 and c-myc, other oncogenes located on the 8q23–24 region might be involved in this process. Therefore, the present study aims to correlate DNA copy number status of a series of genes at 8q23–24 in colorectal cancer at high resolution in correlation to metastatic disease. |i|Materials and Methods|/i|: Thirty-two cases of colorectal cancer, 10 stage B1, 10 B2 and 12 D (Astler–Coller) with their corresponding liver metastasis and one colorectal cell line (colo205, previously analyzed by array-CGH), were included in this study. A chromosome 8 specific MLPA probe mixture was used to analyze the presence of DNA copy number changes. The probe mixture contained 29 probes covering
Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Masayuki Kobayashi) announced today that the results of a Phase III clinical trial of TS-1 conducted in Japan on metastatic colorectal cancer (SOFT* Study) were published in the digital version of The Lancet Oncology, a leading medical journal in the field of oncology research.. The SOFT Study enrolled 512 patients with metastatic colorectal cancer to verify that the SOX/Bev regimen (TS-1/oxaliplatin plus bevacizumab) is non-inferior to mFOLFOX6/Bev (modified regimen of 5-FU/l-LV/oxaliplatin plus bevacizumab), which is one of the standard regimens. The primary endpoint was progression-free survival (PFS). Median PFS was 11.5 months in the mFOLFOX6/Bev group and 11.7 months in the SOX/Bev group (hazard ratio 1.04, non-inferiority p value 0.014). Adverse events of Grade 3 or higher (Common Terminology Criteria for Adverse Events) in the SOX/Bev group were sensory neuropathy (10.0%), diarrhea (9.2%), neutropenia (8.8%), hypertension (6.0%), ...
March is National Colorectal Cancer Awareness Month. This health observance was created in 2000 to increase awareness of the importance of regular screening to save lives and decrease the national burden of colorectal cancer (cancer of the colon or rectum). Colorectal cancer is the second leading cause of cancer-related death in the United States, after lung/bronchus cancer. In 2002, a total of 139,534 adults in the United States had colorectal cancer diagnosed, and 56,603 adults died from colorectal cancer (1). The impact of colorectal cancer can be lessened through regular screening, which has been shown to reduce incidence and mortality (2). CDC directly supports National Colorectal Cancer Awareness Month through its Colorectal Cancer Prevention and Control Initiative, which includes Screen for Life: National Colorectal Cancer Action Campaign (SFL), research related to colorectal cancer prevention and control, and activities aimed at increasing colorectal cancer screening. In addition, ...
Addition of selective internal radiation therapy (SIRT) failed to improve progression-free survival in non-resectable colorectal cancer liver metastases.
TY - JOUR. T1 - Colorectal cancer screening and prevention. AU - Wilkins, Jeff T. AU - McMechan, Danielle. AU - Talukder, Asif. PY - 2018/5/15. Y1 - 2018/5/15. N2 - Colorectal cancer is a common cause of morbidity and mortality in the United States. Most colorectal cancers arise from preexisting adenomatous or serrated polyps. The incidence and mortality of colorectal cancer can be reduced with screening of average-risk adults 50 to 75 years of age. Randomized controlled trials show evidence of reduced colorectal cancer-specific mortality with guaiac-based fecal occult blood tests and flexible sigmoidoscopy. There are no randomized controlled trials on the effectiveness of colonoscopy to reduce colorectal cancer-specific mortality; however, several randomized controlled trials comparing colonoscopy with other strategies are in progress. The best available evidence supporting colonoscopy is from prospective cohort studies that demonstrate decreased incidence of colorectal cancer and colorectal ...
Background: Treatment of metastatic colorectal cancer to the liver is not uniform. We describe the management of metastatic colorectal cancer of the liver at a single institution during a 10-year period. Methods: From January 1, 1990, through December 31, 1999, 174 patients were identified from the tumor registry at the University of Alabama at Birmingham with a diagnosis of metastatic colorectal cancer to the liver. Patient, tumor, laboratory, operative, and adjuvant therapy factors were analyzed, with overall survival as the endpoint. Log-rank tests were used for univariate analysis. Cox-proportional hazards model for multivariate analysis, and Kaplan-Meier curves were used for graphical representation of survival. Significance was defined as P
Colorectal cancer is one of the most common cancer diagnoses and undergoing colorectal cancer surgery is reported to be associated with physical symptoms and psychological reactions. Social support is described as important during the postoperative period. The purpose of this paper was to describe how patients experience the early postoperative period after colorectal cancer surgery.. Interviews according a phenomenological approach were performed with 13 adult participants, within 1 week after discharge from hospital. Data were collected from August 2006 to February 2007. Analysis of the interview transcripts was conducted according to Giorgi.. The essence of the phenomenon was to regain control over ones body in the early postoperative period after colorectal cancer surgery. Lack of control, fear of wound and anastomosis rupture, insecurity according to complications was prominent findings.. When caring for these patients it is a challenge to be sensitive, encourage and promote patients to ...
TY - JOUR. T1 - Additional lymph node examination from entire submission of residual mesenteric tissue in colorectal cancer specimens may not add clinical and pathologic relevance. AU - Kim, Young Min. AU - Suh, Jae Hee. AU - Cha, Hee Jeong. AU - Jang, Se J.. AU - Kim, Mi Jung. AU - Yoon, Sunoch. AU - Kim, Baekhui. AU - Chang, Heejin. AU - Kwon, Youngmee. AU - Hong, Eun Kyung. AU - Ro, Jae Y.. PY - 2007/5. Y1 - 2007/5. N2 - The examination of lymph nodes in colorectal cancer is a critical procedure for determining the stage, which determines prognosis and need for adjuvant therapy. The current recommendation is to harvest at least 12 lymph nodes by conventional manual node dissection (MND). Recent studies have suggested that all lymph nodes in mesenteric tissue should be retrieved using a special method such as the entire submission of residual mesenteric tissue (ESMT) after MND. We investigated the efficacy of ESMT with its potential impact on the pN stage. After an MND in 48 consecutive ...
Estrogen plays an important role in the development of some cancers. However, previous studies on the influence of estrogen on colorectal cancer (CRC) have had conflicting conclusions, and there have been few reports on estrogens and liver metastasis. The aim of this study was to explore the prognostic impact of estrogens on CRC with liver metastasis. Eighty-six patients with CRC including 43 synchronous liver metastases were studied. Estrogen receptor β (ERβ) levels were assayed by immunohistochemistry in liver metastasis, CRC and adjacent normal tissues. Serum estrogen levels were measured by radioimmunoassay. The correlation between staining, clinicopathological parameters, and prognostic power were analyzed statistically. Significant differences were found in ERβ expression between liver metastasis (P = 0.012) and CRC (P = 0.002) compared to adjacent normal tissues. Serum estrogen levels in patients with liver metastases were significantly lower than those without liver metastasis (P = 0.012).
Our previous study found that male sex, age of 50 years or more and family history of colorectal cancer were independent risk factors for detecting advanced colorectal neoplasia.10 In the ensuing discussion, it has been suggested that the observed disparity of advanced neoplasia risk between men and women might have merely reflected sex-based differences in smoking patterns.25 In the present study, we used a new dataset to derive and validate a model for the detection of advanced colorectal neoplasia that included smoking status and other potential confounders, such as age, sex, family history of colorectal cancer, and Body Mass Index. We confirmed previously identified associations, and also found that smoking ≥10 pack-years, and Body Mass Index ≥30 kg/m2 were independent risk factors for detecting advanced colorectal neoplasia. Our study corroborated previously identified risk factors for advanced colorectal neoplasia;10-16 it also, for the first time, combined all five important factors ...
Looking for online definition of Colorectal neoplasms in the Medical Dictionary? Colorectal neoplasms explanation free. What is Colorectal neoplasms? Meaning of Colorectal neoplasms medical term. What does Colorectal neoplasms mean?
In this large prospective study, higher intake of marine n-3 fatty acids was not associated with risk of distal colorectal adenoma. In addition, no significant associations were observed between this dietary variable and risks of small adenoma, distal colon adenoma, and rectal adenoma, although a nonsignificant, suggestive, inverse association was noted for large adenoma. Similarly, we found no significant associations between n-3/n-6 ratio and risks of distal colorectal adenoma.. We did find a suggestively decreased risk of large adenoma associated with higher dietary marine n-3 fatty acid intake (RR, 0.74; 95% CI, 0.54-1.01). Interestingly, we also noted that high n-3 intake was associated with a nonsignificant increase in risk of small adenoma. We thus conducted a post hoc analysis and found that among women with a diagnosis of adenoma, those with high dietary intake of marine n-3 fatty acids had a 46% lower odds of having a large adenoma versus a small adenoma. In combination, these results ...
Meet the Rhode Island colorectal cancer treatment team at the Colorectal Cancer Multidisciplinary Clinic from Lifespan Health System.
TY - JOUR. T1 - Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. AU - Bartlett, David L.. AU - Libutti, Steven K.. AU - Figg, William D.. AU - Fraker, Douglas L.. AU - Richard Alexander, H.. PY - 2001/1/1. Y1 - 2001/1/1. N2 - Background. Unresectable colorectal liver metastases are a significant clinical problem. Isolated hepatic perfusion (IHP) is a regional treatment technique that delivers high dose chemotherapy, biologic agents, and hyperthermia via a completely isolated vascular recirculating perfusion circuit as a means of regionally treating liver tumors. This study presents our results of IHP with tumor necrosis factor (TNF) plus melphalan or IHP with melphalan alone followed by infusional floxuridine (FUDR) and leucovorin in patients with advanced or refractory unresectable hepatic colorectal metastases. Methods. Fifty-one patients with unresectable colorectal hepatic metastases underwent a 60-minute IHP with 1.5 mg/kg melphalan and hyperthermia ...
This study examined associations between metformin exposure and colorectal cancer-specific mortality among patients with stage I-III colorectal cancer receiving treatment for diabetes. For overall metformin exposure, the risk of colorectal cancer-specific mortality was 39% lower in metformin-treated diabetics, versus diabetics not receiving metformin, but did not reach the conventional threshold for statistical significance (P = 0.06).. This result is consistent with the findings from 2 previous single-center studies of metformin exposure and survival in colorectal cancer (15, 16). In a study of diabetic patients with stage I-IV disease by Lee and colleagues, metformin exposure for a minimum of 6 months was associated with a significant 34% lower risk of colorectal cancer-specific mortality (16). The results from this study have, however, been questioned due to the possible presence of immortal time bias (17).. In a study by Garrett and colleagues, of diabetic patients with stage I-IV colorectal ...
TY - JOUR. T1 - NAT2 fast acetylator genotype is associated with an increased risk of colorectal cancer in Taiwan. AU - Huang, Chi Chou. AU - Chien, Wen Pin. AU - Wong, Ruey Hong. AU - Cheng, Ya Wen. AU - Chen, Meng Cheng. AU - Chou, Ming Chih. AU - Lee, Huei. PY - 2007/7. Y1 - 2007/7. N2 - In Taiwan, colorectal cancer has one of the highest rates of increased incidence in the past two decades. Heterocyclic amines from dietary cooked meats are metabolically activated by NAT2 (N-acetyltransferase 2), which are associated with colorectal cancer incidence. Thus, the NAT2 fast acetylator genotype may be associated with colorectal cancer risk. However, the association between the NAT2 genotype and colorectal cancer risk is not clearly understood. We conducted a study with 244 primary colorectal cancer cases and 299 cancer-free healthy control subjects to verify the association of NAT2 polymorphisms with the risk of Taiwanese colorectal cancer. Our data showed that subjects with the NAT2 W/W ...
Licorice and its components have been reported to posses various anti-tumor activities, but its active ingredients and underlying mechanisms are not well understood yet. In the present study, a group of representative licorice-derived compounds that could be detected in rat plasma or urine were screened for anti-tumor activity. Among these compounds, isoangustone A (IAA) was found to promptly Inhibit the viability of SW480 human colorectal adenocarcinoma cells in a time- and concentration-dependent manner. Further analyses indicate that IAA activated caspase-dependent pro-apoptotic signaling and induced significant apoptosis, while had little effect on cell cycle. IAA strongly inhibited Akt phosphorylation within 5 min; however, overexpression of constitutively activated Akt could not rescue IAA-mediated inhibition, indicating that inhibition of Akt was not involved in IAA-induced apoptosis. Further examinations show that IAA induced dissipation of mitochondria membrane potential and release of ...
A simple screening may save your life. Thats why cancer specialists encourage people to consider screening for colorectal cancer. And there is no time like the present, especially since March is National Colorectal Cancer Awareness Month.. According to the National Cancer Institute, the number of new colorectal cancer cases and deaths is declining, except in adults younger than 55 years. In the United States, colorectal cancer remains the second leading cause of cancer-related deaths in men and women. The NCI estimated last year there were 140,250 new cases of colon cancer and 50,630 deaths caused by the disease.. We asked Douglas Rex, MD, a Distinguished Professor of Medicine at Indiana University School of Medicine and a researcher at the IU Simon Cancer Center, about the disease and screening options. Rex is a leading authority on colorectal cancer screening and colonoscopy.. As you know, the American Cancer Society changed its recommended age of first screenings from 50 to 45 for people of ...
PURPOSE: In this analysis, we compared costs and explored the cost-effectiveness of subsequent-line treatment with cetuximab or panitumumab in patients with wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) after previous chemotherapy treatment failure. Data were used from ASPECCT (A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer), a Phase III, head-to-head randomized noninferiority study comparing the efficacy and safety of panitumumab and cetuximab in this population.
CHICAGO -- Bevacizumab (Avastin) given before surgery for curative resection of liver metastases from colorectal cancer did not increase the risk of bleeding, researchers reported here.
TY - JOUR. T1 - Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients with Elevated CEA. AU - Gulhati, Pat. AU - Yin, Jun. AU - Pederson, Levi. AU - Schmoll, Hans Joachim. AU - Hoff, Paulo. AU - Douillard, Jean Yves. AU - Hecht, J. Randolph. AU - Tournigand, Christophe. AU - Tebbut, Niall. AU - Chibaudel, Benoist. AU - Gramont, Aimery De. AU - Shi, Qian. AU - Overman, Michael James. N1 - Publisher Copyright: © 2020 The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected] PY - 2020/11/1. Y1 - 2020/11/1. N2 - Background: Carcinoembryonic antigen (CEA) levels are used in conjunction with imaging to monitor response to systemic therapy in metastatic colorectal cancer (mCRC). We sought to identify a threshold for CEA change from baseline to predict progressive disease (PD) in mCRC patients receiving first-line therapy. Methods: Patients from ...
Patients treated by liver resection had the best outcome, while patients with extrahepatic diseases had poor prognosis. The prognosis of patients treated by regional chemotherapy improved significantly with the advent of irinotecan and better selection.
The clever study by Ahlquist and colleagues adds to growing doubt about the value of fecal occult blood tests (FOBTs) for colorectal cancer screening. The authors recognized that patients with resected colorectal cancer would have regular colonoscopy (or barium enema) and obtained stools from them before their annual structural examinations. In contrast to previous studies, they did complete evaluations in persons with both positive and negative FOBTs, providing an unbiased assessment of sensitivity and specificity. The study showed that fecal occult blood tests failed to detect 70% of cancers and 80% of large (≥ 2.0 cm) polyps. HemoQuant, a more expensive and cumbersome test, offered no advantage over Hemoccult at matched sensitivity. Study strengths included large sample size, prospective design, careful follow-up, and meticulous laboratory methods. The study population and test conditions differed somewhat from previous studies. Stool samples were mailed in sealed containers, although this ...
Egypt has extensive environmental pollution and the highest proportion of early-onset colorectal cancers in patients under age 40 in the world (35 percent of total colorectal cancers). These tumors show high mucin production, more undifferentiation, and a lower prevalence of k-ras mutations that tumors of US patients. The molecular and pathological patterns of these tumors could indicate possible environmental exposures. Organochlorine pesticides, polycyclic aromatic hydrocarbons (PAHs), heterocyclic amines (HCAS), and polychlorinated biphenyls (PCBs) have been correlated with colon carcinogenesis in experimental animals. Egyptians are highly exposed to these carcinogens in farming, cooked foods, combustion products, and polluted air and water. Egypt offers a unique opportunity and a natural experiment for a population study to investigate the impact of organochlorine pesticides and other environmental carcinogens on early-onset colorectal cancer. In order to better understand the association ...
Through local and national efforts we plan to raise awareness about young onset colorectal cancer and remove the stigma of colorectal cancer, said Kim Newcomer, Never2Young program manager at the Colorectal Cancer Alliance. One of the most powerful tools we have is education. We must take this message directly to young people and the medical community.. Since 1994, diagnosis of colorectal cancer in young adults, ages 20-49, have increased by 51%, according to the National Cancer Institute. Colorectal cancer is highly treatable if detected early, but because the standard screening age is 50, young people with the disease tend to be diagnosed at later stages. The N2Y Advisory Board provides a strong voice for the young onset colorectal cancer community by going straight to the source: All of the members have been directly impacted by colorectal cancer, either as a survivor or patient. Members flew into Washington for the meeting from across the country. It is important for me to be here as an ...
Colorectal cancers develop through several pathways, including the adenoma-carcinoma sequence and colitis-associated carcinogenesis. An altered intestinal microflora has been reported to be associated with the development and progression of colorectal cancer via these pathways. We identified Lactobacillus casei-derived ferrichrome as a mediator of the bacterial anti-tumor effect of colorectal cancer cells through the upregulation of DDIT3. In this study, we investigated the anti-tumor effects of ferrichrome on precancerous conditions and cancer cells associated with sporadic as well as colitis-associated colorectal cancer. SRB and MTT assays were performed to assess growth inhibition in vitro. Eighteen organoids were prepared from biopsy specimens obtained by colonoscopy. An AOM-DSS carcinogenesis model and xenograft model of colorectal cancer cells were generated for the assessment of the tumor suppressive effect of ferrichrome in vivo. Ferrichrome inhibited the cell growth of colorectal cancer cells
If you present symptoms of colorectal cancer, open and direct communication with your physician could save your life, suggest the results of a study by researchers at Virginia Commonwealth University Massey Cancer Center.. Colorectal cancer (CRC) is the second leading cause of cancer death in the U.S., but if diagnosed early, patients have a five-year survival rate of 91 percent. In a study recently published in the journalPatient Education and Counseling, Laura A. Siminoff, Ph.D., and a team of researchers conducted in-depth interviews with 242 patients diagnosed with CRC in the six months preceding the study. Interview responses, confirmed by a review of the participants medical records, identified several factors that contribute to diagnostic delay. Diagnostic delay refers to the time from the first visit in which the patient reports symptoms indicative of CRC through the date of diagnosis.. The study highlights the importance of communication between doctors and patients, says Siminoff, ...
C-reactive protein is a sensitive but nonspecific systemic marker of inflammation. Several prospective studies have investigated the association of prediagnostic circulating C-reactive protein concentrations with the development of colorectal cancer, but the results have been inconsistent. We performed a systematic review of prospective studies of the association between prediagnostic measurements of circulating high-sensitivity C-reactive protein and development of invasive colorectal cancer. Authors of original studies were contacted to acquire uniform data. We combined relative risks (RR) for colorectal cancer associated with a one unit change in natural logarithm-transformed high-sensitivity C-reactive protein using inverse variance weighted random effects models. We identified eight eligible studies, which included 1,159 colorectal cancer cases and 37,986 controls. The summary RR per one unit change in natural log-transformed high-sensitivity C-reactive protein was 1.12 (95% confidence intervals
Melanomul conjunctival Melanomul conjunctival este foarte rar. Pot exista motive ereditare pentru renașterea lor. Melanomul în iris apare în partea din față, partea colorată a ochiului.
A stool test known as the fecal immunochemical test (FIT) is accurate in diagnosing most colorectal cancers, according to a meta-analysis published in the Annals of Internal Medicine.. Screening is crucial for the prevention and early detection of colorectal cancer. The American Cancer Society currently recommends that people at average risk of colorectal cancer begin being screened for colorectal cancer at the age of 50. Screening may need to begin at a much earlier age for people with a personal or family history of adenomatous polyps, FAP, HNPCC, colorectal cancer, or chronic inflammatory bowel disease.. There are several available screening strategies for colorectal cancer, including colonoscopy, sigmoidoscopy, fecal occult blood test (FOBT), and FIT. Colonoscopy is considered the gold standard in screening for colorectal cancer. The U.S. Preventive Services Task Force (USPSTF) recommends that people between ages 50 and 75 get screened by colonoscopy every 10 years or sigmoidoscopy every ...
Lynch syndrome (Hereditary Nonpolyposis Colorectal Cancer, HNPCC) is the most common hereditary syndrome predisposing to colorectal cancer, accounting for 1-3% of all colorectal cancer. This multi-organ cancer predisposition syndrome is caused by mutations in the mismatch repair (MMR) genes, especially MLH1 and MSH2, and to lesser extents MSH6 and PMS2, which lead to widespread genetic instability and thus microsatellite instability (MSI). Hereditary cancer often manifests in two or more tumours in a single individual; 35-40% of Lynch syndrome patients have synchronous or metachronous tumours of the two major Lynch syndrome-related cancers: colorectal and endometrial.. The main purposes of the work underlying this thesis were to identify persons at risk of Lynch syndrome or other types of hereditary colorectal cancer, to estimate the cancer risks associated with these predispositions and to identify the underlying genetic causes.. A population-based cohort of 78 persons with double primary ...
Vitamin D is well-regarded in its ability to maintain a healthy immune system: Some rich sources of it include egg yolks, shiitake mushrooms, and seafood.. In their study, the researchers wanted to explore how supplementing vitamin D to standard chemotherapy can influence the progression of cancer among people who have metastatic colorectal cancer.. For their randomized controlled trial, the team gathered 139 participants who had untreated metastatic colorectal cancer. Before the trial began, the researchers noted that only nine percent of the participants had the needed amount of vitamin D in their bodies. The researchers then grouped the participants into a high-dose group and a low-dose group: The former was given vitamin D during treatment, while the latter took standard chemotherapy sessions.. The high-dose group received 8,000 international units (IU) of vitamin D daily for two weeks. Afterward, the researchers lowered the dose to 4,000 IU per day. Meanwhile, the low-dose group only took ...
BACKGROUND: Colorectal cancer incidence is rapidly rising in many Asian countries, with rates approaching those of Western countries. This study aimed to evaluate the prevalence and trends of colorectal adenomas by age, sex, and risk strata in asymptomatic Koreans. METHODS: Cross-sectional study of 19,372 consecutive participants aged 20 to 79 years undergoing screening colonoscopy at the Center for Health Promotion of the Samsung Medical Center in Korea from January 2006 to June 2009. RESULTS: Among participants at average risk, those without a history of colorectal polyps or a family history of colorectal cancer, the prevalence of colorectal adenomas and advanced adenomas were 34.5% and 3.1%, respectively, in men and 20.0% and 1.6%, respectively, in women. The prevalence of adenomas increased with age in both men and women, with a more marked increase for advanced adenoma. Participants with a family history of colorectal cancer or with a history of colorectal polyps had significantly higher ...
High blood concentrations of C-reactive protein (CRP) have been associated with elevated risk of colorectal cancer in several prospective studies including the European Prospective Investigation into Cancer and Nutrition (EPIC), but it is unknown whether these observations reflect a causal relationship. We aimed to investigate whether CRP genetic variants associated with lifelong higher CRP concentrations translate into higher colorectal cancer risk. We conducted a prospective nested case-control study within EPIC including 727 cases diagnosed between 1992 and 2003 and 727 matched controls selected according to an incidence-density sampling protocol. Baseline CRP concentrations were measured in plasma samples by a high sensitivity assay. Tagging single nucleotide polymorphisms (SNPs) in the CRP gene (rs1205, rs1800947, rs1130864, rs2808630, rs3093077) were identified via HapMap. The causal effect of CRP on colorectal cancer risk was examined in a Mendelian Randomization approach utilizing ...
While colonoscopy screening is widely used in several European countries and the United States, there are no randomized trials to quantify its benefits. The Nordic-European Initiative on Colorectal Cancer (NordICC) is a multinational, randomized controlled trial aiming at investigating the effect of colonoscopy screening on colorectal cancer (CRC) incidence and mortality. This paper describes the rationale and design of the NordICC trial. Men and women aged 55 to 64 years are drawn from the population registries in the participating countries and randomly assigned to either once-only colonoscopy screening with removal of all detected lesions, or no screening (standard of care in the trial regions). All individuals are followed for 15 years after inclusion using dedicated national registries. The primary end points of the trial are cumulative CRC-specific death and CRC incidence during 15 years of follow-up. POWER ANALYSIS: We hypothesize a 50 % CRC mortality-reducing efficacy of the colonoscopy ...
Transforming growth factor-beta (TGF-beta) is a pluripotent cytokine that can have both tumor suppressing and tumor promoting effects on epithelial cells. It is unclear what determines when TGF-beta and its signaling pathway act predominantly as a tumor suppressor pathway or as a tumor-promoter pathway and whether TGF-beta can have both classes of effects concurrently on a cell. We investigated the effect of TGF-beta on anoikis in colorectal cancer cell lines sensitive to TGF-beta-mediated growth inhibition to determine if the context of the cells could be one of the factors that would affect whether TGF-beta exerts tumor suppressor or oncogene activity on colon cancer cells. We observed variable effects of TGF-beta on anoikis in these cell lines, even though they all are growth-inhibited by TGF-beta. Thus, we show that TGF-beta has variable effects on anoikis in colon cancer cell lines that likely reflects the effects of concurrent gene mutations in the cancer cells and the activation state of ...
Colorectal cancer is the second leading cause of cancer death in BC after lung cancer. The lifetime risk of dying of colorectal cancer is about 3%. Most, if not all, colorectal cancers are believed to develop from adenomatous polyps[1] over a period of about 10 years. Screening for colorectal cancer offers the opportunity to reduce mortality by the earlier detection of invasive disease and by the removal of precancerous polyps, thus preventing the development of colorectal cancer.
Metastatic disease is the main cause of death in patients with colorectal cancer and the most frequent location of metastases is in the liver. The treatment of liver metastases of colorectal origin is multimodal and should be based on a multidisciplinary team decision. A systematic review of the literature revealed that the number of liver metastases, their maximum size, CEA level, advanced age of the patients, and presence of extrahepatic disease are no longer contraindications to liver resection. The resectability rate of colorectal liver metastases increased from 10 to almost 40%, enabling 5-year overall survival rates higher than 30%. Short-term and long-term results achieved by simultaneous resection (SR) are similar to those achieved by staged resections in patients with synchronous colorectal liver metastases. Whenever possible, major hepatectomies should be replaced by ultrasound-guided limited liver resections, and primary tumor should be approached in a minimally invasive manner. Even
The frequency of the CHEK2 1100delC among colorectal cancer patients was 2.6% (17/662). The proportions were 1.3% (2/149) and 2.9% (15/513) in familial and non-familial cases, respectively. These frequencies are not significantly higher (odds ratio (OR) 1.393, 95% confidence interval (CI) 0.775 to 2.504, p=0.266, for all cases; OR 0.720, 95% CI 0.172 to3.020, p=1.000 for familial cases and OR 1.592, 95% CI 0.863 to 2.939, p=0.134 for non-familial cases) than in the normal population, compared with the geographically adjusted population frequency of 1.9%. These results suggest that the 1100delC variant is not significantly associated with familial colorectal cancer or with colorectal cancer risk in the population; however, larger studies would be needed to detect or exclude any slight increase with a high confidence. In the group of non-familial colorectal cancer cases, there was no difference in allele frequency among those patients with a personal or family history of breast cancer (3/104, ...
TY - JOUR. T1 - The VTI1A-TCF4 colon cancer fusion protein is a dominant negative regulator of Wnt signaling and is transcriptionally regulated by intestinal homeodomain factor CDX2. AU - Davidsen, Johanne. AU - Larsen, Sylvester. AU - Coskun, Mehmet. AU - Gögenür, Ismail. AU - Dahlgaard, Katja. AU - Bennett, Eric Paul. AU - Troelsen, Jesper. PY - 2018/7/5. Y1 - 2018/7/5. N2 - Sequencing of primary colorectal tumors has identified a gene fusion in approximately 3% of colorectal cancer patients of the VTI1A and TCF7L2 genes, encoding a VTI1A-TCF4 fusion protein containing a truncated TCF4. As dysregulation of the Wnt signaling pathway is associated with colorectal cancer development and progression, the functional properties and transcriptional regulation of the VTI1A-TCF4 fusion protein may also play a role in these processes. Functional characteristics of the VTI1A-TCF4 fusion protein in Wnt signaling were analyzed in NCI-H508 and LS174T colon cancer cell lines. The NCI-H508 cell line, ...
Note: This study was performed as part of a multicenter cancer screening comparative effectiveness research project, SEARCH (Screening Effectiveness and Research in Community-based Healthcare), which was supported by grant UC2CA148576 from the National Cancer Institute of the National Institutes of Health.. Disclaimer: The contents of this report are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or the National Cancer Institute.. Acknowledgment: The authors thank the SEARCH coordinators (Debra Bonollo, Shawn Gagne, Gabrielle Gundersen, Denise Schwarzkopf, and Cyndee Yonehara) for coordinating data collection on this project, the medical records auditors (Amy Stone Murai, RN, MS, APRN-C, CHRC, at Kaiser Permanente Hawaii; Janet Guilbert and Doris Hoyer at Reliant Medical Group; Elie Castro and Melanie Currier at the Group Health Research Institute; and Kim Olsen at Kaiser Permanente Northwest), and Hirut Fassil ...
Introduction : Cancer cells, compared to normal cells, are under increased oxidative stress associated with oncogenic transformation, alterations in metabolic activity, and increased generation of reactive oxygen species. Material and methods : We investigated the ability of vitamin C to...
Laparoscopic colorectal cancer surgery by a colon lifting-up technique that decreases the number of access ports: comparison by propensity scoring of short-term
Jin, H; Leng, Q; Li, C (15 August 2012). "Dietary flavonoid for preventing colorectal neoplasms". Colorectal Cancer Group. ... Prinz-Langenohl, R; Fohr, I; Pietrzik, K (2001). "Beneficial role for folate in the prevention of colorectal and breast cancer ... 2001). "A Western-style diet induces benign and malignant neoplasms in the colon of normal C57Bl/6 mice". Carcinogenesis. 22 ( ... Alcohol also increases the risk of cancers of the mouth, esophagus, pharynx and larynx, colorectal cancer, liver cancer, ...
2003). "Down-regulation of drs mRNA in colorectal neoplasms". Jpn. J. Cancer Res. 93 (8): 888-93. doi:10.1111/j.1349-7006.2002. ...
"A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms". ...
... and left-sided colorectal neoplasms after colonoscopy: population-based study". J Natl Cancer Inst. 102 (2): 89-95. doi:10.1093 ... Angiodysplasia of the colon Appendicitis Chronic functional abdominal pain Colitis Colorectal cancer Colorectal polyp ... Tepus, M; Yau, TO (20 May 2020). "Non-Invasive Colorectal Cancer Screening: An Overview". Gastrointestinal Tumors. 7 (3): 62-73 ... May 2010). "Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled ...
Tse, G; Eslick, G.D. (2014). "Cruciferous vegetables and risk of colorectal neoplasms: a systematic review and meta-analysis". ...
22:1-3. Tse, G; Eslick, G.D. (2014). "Cruciferous vegetables and risk of colorectal neoplasms: a systematic review and meta- ...
March 2008). "Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults". JAMA ... Individuals infected with H. pylori may also develop colorectal or gastric polyps, i.e. non-cancerous growths of tissue ... Colorectal Disease. 15 (7): e352-64. doi:10.1111/codi.12284. PMID 23672575. S2CID 5444584. "Helicobacter pylori" (PDF). cdc.gov ... gastric outlet obstruction while colorectal polyps may be the cause of rectal bleeding, anemia, constipation, diarrhea, weight ...
Colorectal cancer is the most common visceral neoplasm in Muir-Torre syndrome patients. It is named for EG Muir and D Torre. A ... Along with neoplasms of the sebaceous gland, this patient developed cerebral neoplasms, characteristic of Turcot syndrome. ... Age of onset of first sebaceous neoplasm: 2 = 2 points. Personal history of Lynch related cancers: No = 0 points, Yes = 1 point ... They include the following: 3 or more relatives with an HNPCC-associated cancer (i.e., colorectal, cancer of the endometrium, ...
... mRNA expression is reduced in colorectal neoplasms due to methylation of the promoter region of MBD4. A majority of ... In colorectal cancers with mutations in MMR genes, co-occurrence of MBD4 mutations were found in 27% of cancers. ... For example, nearly 50% of somatic mutations of the tumor suppressor gene p53 in colorectal cancer are G:C to A:T transitions ... Mutation of MBD4 occurs in about 4% of colorectal cancers. MBD4 mutations also occur in tumor samples of melanoma, ovarian, ...
MBD4 expression is reduced in almost all colorectal neoplasms due to methylation of the promoter region of MBD4. Also MBD4 is ... For example, nearly 50% of somatic mutations of the tumor suppressor gene p53 in colorectal cancer are G:C to A:T transitions ... NEIL1 was also one of six DNA repair genes found to be hypermethylated in their promoter regions in colorectal cancer. Lindahl ... This finding suggests that epigenetic silencing of MBD4 is an early step in colorectal carcinogenesis. In a Chinese population ...
The incidence of MTS in patients with sebaceous neoplasms as high as 14 to 50%. Besides mutations in mismatch repair genes, Wnt ... the most common being colorectal adenocarcinoma. MTS results from defects in DNA mismatch repair genes, MLH1, MSH2, and MSH6, ... SGc accounts for approximately 0.7% of all skin cancers and 0.2 to 4.6% of all malignant cutaneous neoplasms. Notable risk ... While there are markedly increased rates of cutaneous neoplasms in solid organ transplant recipients, there is evidence to ...
People with BHD were once thought to be at higher risk for colorectal polyps and neoplasms, but this has been disproven. The ... colorectal cancer, sarcoma of the leg, lung cancer, melanoma, dermatofibrosarcoma protuberans, basal cell carcinoma, cutaneous ...
... and left-sided colorectal neoplasms after colonoscopy: population-based study". J Natl Cancer Inst. 102 (2): 89-95. doi:10.1093 ... This interval does not apply to people at high risk of colorectal cancer, or to those who experience symptoms of colorectal ... "Colorectal Cancer Prevention and Early Detection" (PDF). American Cancer Society. February 5, 2015. pp. 16-24. Retrieved 2015- ... "Your Medicare Coverage: Colorectal cancer screenings". Medicare.gov. Archived from the original on 2015-12-21. Retrieved 2015- ...
... and left-sided colorectal neoplasms after colonoscopy: population-based study". J Natl Cancer Inst. 102 (2): 89-95. doi:10.1093 ... This interval does not apply to people at high risk of colorectal cancer, or to those who experience symptoms of colorectal ... Colonoscopy is one of the colorectal cancer screening tests available to people in the US who are over 50 years of age. The ... 2017). "Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on ...
H7 Shigella Salmonella Campylobacter jejuni Hemorrhoids Neoplasm - such as colorectal cancer Angiodysplasia Bleeding from a ... Colorectal Dis. 14 (8): 1020-8. doi:10.1111/j.1463-1318.2011.02824.x. PMID 21910819. Oakland, K; Chadwick, G; East, JE; Guy, R ...
... cecal neoplasms MeSH C04.588.274.476.411.184.290 - appendiceal neoplasms MeSH C04.588.274.476.411.307 - colorectal neoplasms ... colorectal neoplasms, hereditary nonpolyposis MeSH C04.588.274.476.411.307.790 - rectal neoplasms MeSH C04.588.274.476.411.307. ... skull base neoplasms MeSH C04.588.149.828 - spinal neoplasms MeSH C04.588.180.260 - breast neoplasms, male MeSH C04.588.180.390 ... bile duct neoplasms MeSH C04.588.274.120.250.250 - common bile duct neoplasms MeSH C04.588.274.120.401 - gallbladder neoplasms ...
... colorectal neoplasms MeSH C06.405.469.860.180.500 - rectal neoplasms MeSH C06.405.469.860.180.500.040 - anus neoplasms MeSH ... cecal neoplasms MeSH C06.301.371.411.184.290 - appendiceal neoplasms MeSH C06.301.371.411.307 - colorectal neoplasms MeSH ... cecal neoplasms MeSH C06.405.249.411.184.290 - appendiceal neoplasms MeSH C06.405.249.411.307 - colorectal neoplasms MeSH ... cecal neoplasms MeSH C06.405.469.491.184.290 - appendiceal neoplasms MeSH C06.405.469.491.307 - colorectal neoplasms MeSH ...
... colorectal neoplasms, hereditary nonpolyposis MeSH C18.452.284.280 - fanconi anemia MeSH C18.452.284.520 - Li-Fraumeni syndrome ...
... colorectal neoplasms, hereditary nonpolyposis MeSH C16.320.700.305 - dysplastic nevus syndrome MeSH C16.320.700.330 - exostoses ...
Paris classification of colorectal neoplasms. In colonoscopy, colorectal polyps can be classified by NICE (Narrow-band imaging ... Untreated colorectal polyps can develop into colorectal cancer. Colorectal polyps are often classified by their behaviour (i.e ... Hereditary nonpolyposis colorectal cancer (HNPCC, also known as Lynch syndrome) is an hereditary colorectal cancer syndrome. It ... Gross appearance of a colectomy specimen containing two colorectal polyps and one invasive colorectal carcinoma Micrograph of a ...
Chakravarthi S, Krishnan B, Madhavan M (1999). "Apoptosis and expression of p53 in colorectal neoplasms". Indian J. Med. Res. ... "Colorectal Cancer Atlas". Archived from the original on January 13, 2016. Colorectal cancer at Curlie Colon cancer survival ... "Colorectal Cancer 2011 Report: Food, Nutrition, Physical Activity, and the Prevention of Colorectal Cancer" (PDF). World Cancer ... The Cancer Genome Atlas The Colorectal Cancer Atlas integrating genomic and proteomic data pertaining to colorectal cancer ...
... can refer to: Small intestine cancer Colorectal cancer This disambiguation page lists articles associated ... with the title Intestinal neoplasms. If an internal link led you here, you may wish to change the link to point directly to the ...
For example, of 113 sequential colorectal cancers, only four had a missense mutation in the DNA repair gene MGMT, while the ... ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... The term "neoplasm" is a synonym of "tumor". "Neoplasia" denotes the process of the formation of neoplasms/tumors, the process ... p. Neoplasm. ISBN 978-0781733908. "II Neoplasms". International Statistical Classification of Diseases and Related Health ...
... benign or malignant neoplasms Large bowel obstruction caused by colorectal cancer, inflammatory bowel disease, volvulus, fecal ...
1996). "Spontaneous intestinal carcinomas and skin neoplasms in Msh2-deficient mice". Cancer Res. 56 (16): 3842-9. PMID 8706033 ... Mouse models of colorectal cancer and intestinal cancer are experimental systems in which mice are genetically manipulated, fed ... 2002). "Colorectal cancer in mice genetically deficient in the mucin Muc2". Science. 295 (5560): 1726-9. doi:10.1126/science. ... Today we know that the beta-catenin protein (part of the Wnt signaling pathway) is implicated in colorectal carcinogenesis and ...
B-cell neoplasm, breast carcinoma, Burkitt's lymphoma, colorectal adenocarcinoma, carcinoma, cutaneous T cell lymphoma, ...
Types include: esophageal cancer gastric cancer small intestinal cancer colorectal cancer anal cancer v t e. ... Digestive system neoplasms are tumors which affect the digestive system. ...
... a type of colorectal cancer (ICD-10 code: C20) Caldwell 20 or North America Nebula, an emission nebula in the constellation ... a mix of concrete that has a compressive strength of 20 newtons per square millimeter Malignant neoplasm of rectum, ...
... especially for large or ulcerative neoplasms. Recently, the ESD technique is applied to esophageal or colorectal neoplasms in ... The resected size and shape can be controlled, en bloc resection is possible even in a large neoplasm, and neoplasms with ... So this technique can be applied to the resection of complex neoplasms such as large neoplasms, ulcerative non-lifting ... For a reliable en bloc resection of GI neoplasms, a new method of ER called endoscopic submucosal dissection (ESD) has been ...
2005). "Assessment of JC polyoma virus in colon neoplasms". Dis. Colon. Rectum. 48 (1): 86-91. doi:10.1007/s10350-004-0737-2. ... Several studies since 2000 have suggested that the virus is also linked to colorectal cancer, as JCV has been found in ...
Salivary gland neoplasm. *Sarcoma. *Skin cancer. *Small intestine cancer. *Small-cell carcinoma ...
Tse, G; Eslick, G.D. (2014). "Cruciferous vegetables and risk of colorectal neoplasms: a systematic review and meta-analysis". ...
"Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... For other common cancers, including colorectal, breast and prostate cancer, epidemiological studies suggest little or no ... In Europe in 2012 it was the 3rd most diagnosed cancer after breast and colorectal at 417,000 cases.[160] ...
Chronically insufficient intake of folic acid may increase the risk of colorectal, breast, ovarian, pancreas, brain, lung, ... Folate deficiency hinders DNA synthesis and cell division, affecting hematopoietic cells and neoplasms the most because of ... 2007). "A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating ...
neoplasm: Adenocarcinoma. *Familial adenomatous polyposis. *Hereditary nonpolyposis colorectal cancer. Anus. *Squamous cell ...
Colorectal cancer. 5-fluorouracil, folinic acid, oxaliplatin. FOLFOX. There are a number of strategies in the administration of ... Secondary neoplasm[edit]. Development of secondary neoplasia after successful chemotherapy or radiotherapy treatment can occur ... Colorectal, lung, ovarian and brain cancer. 3. $6.56 billion. Trastuzumab. Herceptin. Roche. Breast, esophagus and stomach ... Similar results were found in a study involving colorectal cancer patients treated with the popular FOLFOX regimen.[22] The ...
... of colorectal cancers and 50% of brain cancers. Promoter hypermethylation of LIG4 occurs in 82% of colorectal cancers. Promoter ... see malignant neoplasms). Thus, CpG island hyper/hypo-methylation in the promoters of DNA repair genes are likely central to ... "Curr Colorectal Cancer Rep. 8 (1): 66-81. doi:10.1007/s11888-011-0116-z. PMC 3277709 . PMID 22389639.. ... point out, in a colorectal cancer there are usually about 3 to 6 driver mutations and 33 to 66 hitchhiker or passenger ...
8560-8580) Complex epithelial neoplasms. Carcinoma In situ[edit]. The term carcinoma in situ (or CIS) is a term for cells that ... Thus, in a sequence of 113 colorectal carcinomas, only four had somatic missense mutations in the DNA repair gene MGMT, while ... Puppa G, Sonzogni A, Colombari R, Pelosi G (2010). "TNM staging system of colorectal carcinoma: a critical appraisal of ... and imaging studies in a logical fashion to obtain information about the size of the neoplasm and the extent of its invasion ...
... colorectal cancer and stomach cancer.[19] In females, the most common types are breast cancer, colorectal cancer, lung cancer ... They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... "Screening for Colorectal Cancer". U.S. Preventive Services Task Force. 2008. Archived from the original on 7 February 2015.. ... "Current Colorectal Cancer Reports. 8 (1): 66-81. doi:10.1007/s11888-011-0116-z. PMC 3277709. PMID 22389639.. ...
Mutations in this gene are correlated with gastric, breast, colorectal, thyroid, and ovarian cancers. Loss of function is ... Neoplasm: Tumor suppressor genes/proteins and Oncogenes/Proto-oncogenes. Ligand. Growth factors. ... "Expression and interaction of different catenins in colorectal carcinoma cells". International Journal of Molecular Medicine. 8 ...
en:Colorectal cancer (67) → 대장암 *en:Epilepsy (102) → 뇌전증 *en:Health (138) → 건강 ... en:Neoplasm (40) → 신생물 *en:Nephrotic syndrome (38) → 신증후군 *en:Nervous system disease (4) ...
neoplasm: Adenocarcinoma. *Familial adenomatous polyposis. *Hereditary nonpolyposis colorectal cancer. Anus. *Squamous cell ... The cumulative lifetime risk of colorectal cancer is 39% in patients with juvenile polyposis syndrome.[3] ...
neoplasm: Adenocarcinoma. *Familial adenomatous polyposis. *Hereditary nonpolyposis colorectal cancer. Anus. *Squamous cell ...
Srikumar Chakravarthi; Baba Krishnan; Malathy Madhavan (1999). "Apoptosis and expression of p53 in colorectal neoplasms". ... "Colorectal Cancer 2011 Report: Food, Nutrition, Physical Activity, and the Prevention of Colorectal Cancer" (PDF). World Cancer ... The Colorectal Cancer Atlas integrating genomic and proteomic data pertaining to colorectal cancer tissues and cell lines have ... Main article: List of people diagnosed with colorectal cancer. In the United States, March is colorectal cancer awareness month ...
... and colorectal cancer. Therefore, immunity against hCG has applications such as imaging of cancer cells, selective delivery of ... hCG was discovered to be expressed in certain kinds of malignant neoplasms, including breast cancer, adenocarcinoma of the ... CA 72-4 and CEA are independent prognostic factors in colorectal cancer". Int J Cancer. 101 (6): 545-548. doi:10.1002/ijc.90009 ...
neoplasm: Adenocarcinoma. *Familial adenomatous polyposis. *Hereditary nonpolyposis colorectal cancer. Anus. *Squamous cell ...
July 2007). "A temporal association between folic acid fortification and an increase in colorectal cancer rates may be ... Folate deficiency hinders DNA synthesis and cell division, affecting hematopoietic cells and neoplasms the most because of ... may increase the risk of colorectal, breast, ovarian, pancreas, brain, lung, cervical, and prostate cancers.[7][39][40][41][42] ...
Colorectal surgery. *Eye surgery netra shashtrachikitse*. *General surgery. *Neurosurgery. *Oral and maxillofacial surgery ...
Endocrine(英语:Endocrine gland neoplasm). *Prolactinoma(英语:Prolactinoma). *Multiple endocrine neoplasia(英语:Multiple endocrine ... 大肠息肉(英语:colorectal polyp): 珀茨-杰格斯综合征 ... Adnexal and skin appendage(英语:Adnexal and skin appendage neoplasms) (8390-8429). *汗腺 *Hidrocystoma(英语:Hidrocystoma) ... Ductal, lobular, and medullary(英语:Ductal, lobular, and medullary neoplasms) (
Multiple myeloma/plasma cell neoplasm. *Myelodysplastic syndromes. *Mucosa-associated lymphoid tissue lymphoma ...
Male Genitals - Prostate Neoplasms»։ Pathology study images։ University of Virginia School of Medicine։ Արխիվացված է օրիգինալից ... including colorectal, breast and prostate cancer, epidemiological studies suggest little or no association between total fruit ...
For example; a patient with a history of colorectal cancer treated with a colectomy, now presenting with abdominal adhesions. ... Z08) Follow-up examination after treatment for malignant neoplasms. *(Z09) Follow-up examination after treatment for conditions ...
neoplasm: Adenocarcinoma. *Familial adenomatous polyposis. *Hereditary nonpolyposis colorectal cancer. Anus. *Squamous cell ... "Islet Cell Tumors of the Pancreas / Endocrine Neoplasms of the Pancreas". The Sol Goldman Pancreas Cancer Research Center. ... Pancreatic mucinous cystic neoplasms are a broad group of pancreas tumors that have varying malignant potential. They are being ... Kidney cancer is by far the most common cancer to spread to the pancreas, followed by colorectal cancer, and then cancers of ...
Colorectal polyp[edit]. Main article: Colorectal polyp. Colon polyps are not commonly associated with symptoms. Occasionally ... Some polyps are tumors (neoplasms) and others are nonneoplastic (for example, hyperplastic or dysplastic). The neoplastic ones ... They are unlikely to develop into colorectal cancer. About 5% of people aged 60 will have at least one adenomatous polyp of 1 ... The risks of progression to colorectal cancer increases if the polyp is larger than 1 cm and contains a higher percentage of ...
neoplasm: Adenocarcinoma. *Familial adenomatous polyposis. *Hereditary nonpolyposis colorectal cancer. Anus. *Squamous cell ...
Journal Colorectal Dis. Pub Med. 13 (10): 1138-41. doi:10.1111/j.1463-1318.2010.02432.x. PMID 20874797.. ... Neoplasms, benign or malignant. *Intussusception. *Volvulus. *Superior mesenteric artery syndrome, a compression of the ...
Individuals at average-risk for colorectal cancer should have another screening after ten years if they get a normal result and ... in-situ neoplasm. ... American Cancer Society Colorectal Cancer Advisory Group; Us ... "Colorectal cancer screening and surveillance: Clinical guidelines and rationale-Update based on new evidence". Gastroenterology ... the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology". Gastroenterology. 134 (5): 1570- ...
... which may be benign neoplasms) or else a malignant neoplasm (cancer). These neoplasms are also indicated, in the diagram below ... "Curr Colorectal Cancer Rep. 8 (1): 66-81. doi:10.1007/s11888-011-0116-z. PMC 3277709 . PMID 22389639.. ... The Hallmarks of Cancer as evolutionary adaptations in a neoplasm[edit]. In their landmark paper, The Hallmarks of Cancer,[3] ... Cells in neoplasms compete for resources, such as oxygen and glucose, as well as space. Thus, a cell that acquires a mutation ...
Many type of cancers, including colorectal cancer and cancer of the urinary bladder, may cause acute or chronic blood loss, ... and a number of neoplasms of the bone marrow.[1] Causes of increased breakdown include a number of genetic conditions such as ... the chances are higher that bleeding from the gastrointestinal tract could be due to colon polyps or colorectal cancer. ...
Prevalence and Characteristics of Nonpolypoid Colorectal Neoplasms - A Chinese Cohort Study. *Nonpolypoid Colorectal Neoplasms( ... Brief Title : Optimized Endoscopic Submucosal Dissection With Snaring for Colorectal Neoplasm. *Colorectal Neoplasms ... Endoscopic Submucosal Dissection Versus Laparoscopic Resection for Early Colorectal Neoplasms. *Colorectal Neoplasms ... R-21 Colorectal Cancer Screening (CRCS) Pilot Trial. *Colorectal Neoplasms. *Behavioral: CRCS patient decision aid (PtDA) video ...
Sociopsychological Tailoring to Address Colorectal Cancer Screening Disparities: A Randomized Controlled Trial Anthony Jerant, ...
... Sumio Fujinuma and Yoshihiro Sakai ... Then, using the image analyzer, followings were determined with two-dimensional analysis: (1) the size of neoplasms and also (2 ... the size of whole mucosal lesions which was calculated by drawing a perpendicular from the border of the neoplasms; and thus, ...
Sumio Fujinuma and Yoshihiro Sakai, "Study of Superficial Type Colorectal Neoplasms With Central Depression," Diagnostic and ... Study of Superficial Type Colorectal Neoplasms With Central Depression. Sumio Fujinuma and Yoshihiro Sakai ...
Liver Neoplasms Cancer trial. Review trial description, criteria and location information here. ... Pfizer is currently recruiting for the NCT00106054 Colorectal Neoplasms, ... Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases. Back to Search Print Save as PDF Bookmark Trial ... Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases Official Title ICMJE An Open-Label, Multi-Center Phase II ...
Colorectal Neoplasms Cancer trial. Review trial description, criteria and location information here. ... Pfizer is currently recruiting for the NCT00037180 Neoplasm Metastasis, ...
What is Colorectal neoplasms? Meaning of Colorectal neoplasms medical term. What does Colorectal neoplasms mean? ... Looking for online definition of Colorectal neoplasms in the Medical Dictionary? Colorectal neoplasms explanation free. ... colorectal cancer. (redirected from Colorectal neoplasms). Also found in: Dictionary. colorectal cancer. [kō′lərek′təl] ... Colorectal neoplasms , definition of Colorectal neoplasms by Medical dictionary https://medical-dictionary.thefreedictionary. ...
... are at higher risk for synchronous colorectal advanced neoplasms (AN) and cancers. However, it remains unclear whether there is ... Methods Colorectal ANs, which include tubular adenomas ≥10 mm, adenomas with villous histology, high-grade intraepithelial ... The majority of high-grade intraepithelial neoplasms in both groups showed a contiguous component of conventional adenoma. ... neoplasms, and cancers, were collected retrospectively. The groups included ANs with (AN+SP) or without (AN-only) coexisting ...
Disease relevance of Colorectal Neoplasms, Hereditary Nonpolyposis. *High impact information on Colorectal Neoplasms, ... Biological context of Colorectal Neoplasms, Hereditary Nonpolyposis. *Anatomical context of Colorectal Neoplasms, Hereditary ... Gene context of Colorectal Neoplasms, Hereditary Nonpolyposis. *Analytical, diagnostic and therapeutic context of Colorectal ... Gene context of Colorectal Neoplasms, Hereditary Nonpolyposis. *We assessed the prevalence of MSH2 and MLH1 mutations in ...
Neoplasms. Colorectal Neoplasms. Intestinal Neoplasms. Gastrointestinal Neoplasms. Digestive System Neoplasms. Neoplasms by ... Patients with other synchronous colorectal neoplasms in addition to the index neoplasm that are not amenable to complete ... However, if colorectal neoplasms are too large or cannot be removed en bloc endoscopically, operative procedures are required ... ESD has been shown by recent studies to be a safe and effective resection technique for large early colorectal neoplasms. ...
Colorectal cancer screening: a global overview of existing programmes Eline H Schreuders, Arlinda Ruco, Linda Rabeneck, Robert ... Adolescent body mass index and erythrocyte sedimentation rate in relation to colorectal cancer risk Elizabeth D Kantor, Ruzan ... Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer Timothy Robert Church, ... EGFR signalling and oncogenic pathway signature in colorectal cancer Ibrahim Halil Sahin, Ahmet Afsin Oktay ...
Proximal colorectal neoplasms with advanced histology frequently are small or have a nonpolypoid appearance. These findings ... Conclusions: Proximal colorectal neoplasms with advanced histology frequently are small or have a nonpolypoid appearance. These ... Endoscopic appearance of proximal colorectal neoplasms and potential implications for colonoscopy in cancer prevention ... Background: In everyday practice, the use of colonoscopy for the prevention of colorectal cancer (CRC) is less effective in the ...
Establishing Effective Screening Methods for Diagnosing Hereditary Nonpolypoisis Colorectal Cancer ... Establishing Effective Screening Methods for Diagnosing Hereditary Nonpolypoisis Colorectal Cancer Brief description of study. ... Correct identification of Lynch syndrome at the time of colorectal cancer presentation is important. We aim to find best ways ... Patients with newly diagnoised colorectal cancer will be eligible. They will undergo detailed history taking including family ...
Neoplasms, Colorectal Completed Phase 2 Trials for Aflibercept (DB08885). Back to Neoplasms, Colorectal ... Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer. Treatment. * ...
Neoplasms, Colorectal Completed Phase 1 Trials for Capecitabine (DB01101). Back to Neoplasms, Colorectal ... Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer. ... Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer. Treatment. *Bevacizumab ( ... Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer. Treatment. *Capecitabine (DB01101) ...
Lung Neoplasm , bladder cancer , Synovial Cell Cancer , Bronchial Neoplasm , skin cancer , Evaluation for NCI Surgery Branch ...
... N Engl J Med. 2000 Jul ... Background and methods: The clinical significance of a distal colorectal polyp is uncertain. We determined the risk of advanced ... Twenty-three patients with advanced proximal neoplasms (46 percent) had no distal polyps. The prevalence of advanced proximal ...
... learners should know the guidelines for the management of gastroduodenal and coloroectal Neuroendocrine neoplasms, including:. ...
Investigation of the Prevalence and Number of Aberrant Crypt Foci Associated with Human Colorectal Neoplasm. Eiji Sakai, ... Investigation of the Prevalence and Number of Aberrant Crypt Foci Associated with Human Colorectal Neoplasm ... Investigation of the Prevalence and Number of Aberrant Crypt Foci Associated with Human Colorectal Neoplasm ... Investigation of the Prevalence and Number of Aberrant Crypt Foci Associated with Human Colorectal Neoplasm ...
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you dont have an account you can just enter your email address in the email box below ...
... the incidental finding of 18F-FDG uptake with subsequent diagnosis of advanced neoplasm at colorectum has increased. The aim of ... The aim of this study is to analyze the characteristics and risk factors of advanced colorectal neoplasm incidentally detected ... Clinicopathological analysis and risk factors of advanced colorectal neoplasms incidentally detected by 18F-FDG PET-CT. ... Advanced neoplasm was defined as adenoma of at least 10 mm, adenoma with serrated or villous component, high-grade dysplasia, ...
Intraductal papillary mucinous neoplasm of the ileal heterotopic pancreas in a patient with hereditary non-polyposis colorectal ... Key Words: Colorectal neoplasms, Hereditary nonpolyposis, Pancreatic neoplasms, Choristoma Core tip: Intraductal papillary ... Intraductal papillary mucinous neoplasm of the ileal heterotopic pancreas in a patient with hereditary non-polyposis colorectal ... Intraductal papillary mucinous neoplasm of the ileal heterotopic pancreas in a patient with hereditary non-polyposis colorectal ...
You are here: Home / Protocols / Preliminary Clinical Characterization of Serum Biomarkers for Colorectal Neoplasms ... Preliminary Clinical Characterization of Serum Biomarkers for Colorectal Neoplasms Abbreviated Name: Preliminary Clinical ...
... gastric and colorectal cancer but not melanoma or sarcoma) and cancerous tissues (breast, esophageal, colorectal, gastric and ... Monoclonal antibody mAbA33 recognizes a unique cell surface protein of colorectal cancer, the A33 antigen. Phase I/II studies ... In noncolorectal, nonendocrine liver metastases, the role of surgery is less define than in colorectal or neuroendocrine cancer ... have shown highly selective targeting of radio-labeled mAbA33 in patients with metastatic colorectal cancer, opening up the ...
Patients with inflammatory bowel disease colitis have an increased risk of developing colorectal cancer compared with the ... Importance of nonpolypoid (flat and depressed) colorectal neoplasms in screening for CRC in patients with IBD.. @article{ ... colorectal neoplasms in screening for CRC in patients with IBD.}, author={Matthew D. D. Rutter}, journal={Gastrointestinal ... Colorectal Cancer Screening in Primary Care : Update on STOP CRC. Gloria D. Coronado + 1 • Oct 17, 2017 ...
Colorectal neoplasms Tier 1 H96. Colorectal neoplasms Tier 2 H96. Colorectal neoplasms Tier 3 H96. Colorectal neoplasms Tier 4 ... Colorectal neoplasms Tier 1 M96. Colorectal neoplasms Tier 2 M96. Colorectal neoplasms Tier 3 M96. Colorectal neoplasms Tier 4 ... Colorectal neoplasms Tier 1-4 H384 Predesigned 384-well panel for use with SYBR® Green ... Colorectal neoplasms Tier 1-4 M384 Predesigned 384-well panel for use with SYBR® Green ...
23-12-2017 , Colorectal cancer , Book chapter , Article 3. Non-polypoid Colorectal Neoplasms: Characteristics and Endoscopic ... Non-polypoid colorectal lesions account for 5-36% of all colorectal cancers in Western nations and, compared to polypoid ...
Colorectal Neoplasms. *In Saxenda clinical trials, benign colorectal neoplasms (mostly colon adenomas) confirmed by ... Six positively adjudicated cases of malignant colorectal neoplasms were reported in 5 Saxenda-treated patients (0.2%, mostly ... Neoplasms. Medullary thyroid carcinoma. Gastrointestinal Disorders. Acute pancreatitis, hemorrhagic and necrotizing ...
Read more about Small media and client reminders for colorectal cancer screening: current use and gap areas in CDCs Colorectal ... Small media and client reminders for colorectal cancer screening: current use and gap areas in CDCs Colorectal Cancer Control ... Text Reminders in Colorectal Cancer Screening (TRICCS): Protocol for a randomised controlled trial.. Author(s): ... INTRODUCTION: Colorectal cancer (CRC) is an important health problem in Western countries and also in Asia. It is the third ...
Trials have shown laparoscopic colorectal surgery to be safe. We aim to analyze the long-term results from a single national ... We also aim to explore the trend in the length of the learning curve among consultants and colorectal trainees, and determine ... Trials have shown laparoscopic colorectal surgery to be safe. We aim to analyze the long-term results from a single national ... We conclude that laparoscopic colorectal surgery should be the standard treatment option offered to all patients regardless of ...
  • Patients with newly diagnoised colorectal cancer will be eligible. (centerwatch.com)
  • The recent progress in endoscopic technologies and interest in colorectal cancer screening have enabled the diagnosis of a larger number of early colorectal neoplasms, including benign polyps and early cancers. (clinicaltrials.gov)
  • Colonoscopic polypectomy remains the cornerstone of therapy for the majority of colorectal polyps and helps prevent colorectal cancer. (clinicaltrials.gov)
  • 6 mm) or nonpolypoid shape (height less than half of the diameter) of colorectal adenomas and serrated polyps (SPs), with a focus on adenomas with advanced histology, ie, high-grade dysplasia or early CRC and SPs with dysplasia or large size. (nih.gov)
  • Twenty-three patients with advanced proximal neoplasms (46 percent) had no distal polyps. (nih.gov)
  • Precise optical diagnosis of colorectal polyps could improve the cost-effectiveness of colonoscopy and reduce polypectomy-related complications. (cdc.gov)
  • Unlike FAMILIAL POLYPOSIS COLI with hundreds of polyps, hereditary nonpolyposis colorectal neoplasms occur much later, in the fourth and fifth decades. (fpnotebook.com)
  • You're also more likely to get it if you have colorectal polyps , a family history of colorectal cancer, ulcerative colitis or Crohn's disease , eat a diet high in fat, or smoke. (medlineplus.gov)
  • Colorectal cancer may develop from benign polyps (a polyp is a tumour on a stem most commonly found on mucous membranes). (cancerindex.org)
  • AIM: To evaluate the proportion of successful complete cure en-bloc resections of large colorectal polyps achieved by endoscopic mucosal resection (EMR). (biomedsearch.com)
  • METHODS: Studies using the EMR technique to resect large colorectal polyps were selected. (biomedsearch.com)
  • CONCLUSION: EMR is an effective technique for the resection of large colorectal polyps and offers an alternative to surgery. (biomedsearch.com)
  • Untreated colorectal polyps can develop into colorectal cancer. (wikipedia.org)
  • Colorectal polyps are often classified by their behaviour (i.e. benign vs. malignant) or cause (e.g. as a consequence of inflammatory bowel disease). (wikipedia.org)
  • Colorectal polyps are not usually associated with symptoms. (wikipedia.org)
  • There was no significant difference noted between I1307K carriers and noncarriers with regard to the percentage of patients with first-degree relatives with colorectal carcinoma. (cdc.gov)
  • and early colorectal carcinoma in the year 2009. (jpatholtm.org)
  • Conclusions -Colorectal adenoma uPAR, expressed essentially in dysplastic epithelial cells, was upregulated with increasing severity of atypia, and increased notably during the critical transition from severe dysplasic adenoma to invasive carcinoma. (edu.iq)
  • Li BH, Zhao P, Liu SZ, Yu YM, Han M, Wen JK: Matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis. (edu.iq)
  • Scheele J, Stangl R, Altendorf-Hofmann A (1990) Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. (springer.com)
  • Colonoscopy is the definitive test for colorectal cancer. (thefreedictionary.com)
  • Colonoscopy plays an increasingly important role in the diagnosis and treatment of colorectal pathologies. (clinicaltrials.gov)
  • In everyday practice, the use of colonoscopy for the prevention of colorectal cancer (CRC) is less effective in the proximal than the distal colon. (nih.gov)
  • Of the 19,460 subjects who underwent colonoscopy at 11 university hospitals, we analyzed 3,951 consecutive asymptomatic adults with no risk factors for colorectal cancer. (elsevier.com)
  • Therefore, patients with stomach cancer should be regarded as a high-risk group for colorectal neoplasms, and colonoscopy should be recommended for screening. (coloproctol.org)
  • For colorectal cancer, the guideline for early detection of colorectal cancer enacted in 2001 recommends colonoscopy screening test from the age of 50 years for adults with no symptoms [ 7 ]. (coloproctol.org)
  • This study aimed to develop and validate deep learning models that automatically classify colorectal lesions histologically on white-light colonoscopy images. (aigas.ch)
  • White-light colonoscopy images of colorectal lesions exhibiting pathological results were collected and classified into seven categories: stages T1-4 colorectal cancer (CRC), high-grade dysplasia (HGD), tubular adenoma (TA), and non-neoplasms. (aigas.ch)
  • Physician recommendation is a strong predictor of colorectal cancer (CRC) screening adherence, but there are no sufficient data specific to primary colonoscopy screening programs. (nih.gov)
  • An earlier study on the measurement of colorectal endoscopy (e.g., sigmoidoscopy and colonoscopy) found Medicare claims to be an accurate source for measurement of endoscopy use ( 11 ). (aacrjournals.org)
  • At 2 years of follow-up, colonoscopy revealed the presence of adenomas in 25% of patients, and colorectal cancer in 4% of patients. (gastrohep.com)
  • CTC) vs pathology and colonoscopy in the detection of clinically important colorectal neoplasia, defined as at least one proven lesion with a diameter measuring at least 1 cm. (knowcancer.com)
  • In univariate analysis, age of 62.5 years or older, carcinoembryonic antigen (CEA) of at least 3.4 ng/ml, maximum standardized uptake value (SUVmax) of at least 8.0, hypertension, 18F-FDG uptake on the rectosigmoid, and PET-CT for metastasis work-up showed a significant association with advanced neoplasm. (ovid.com)
  • Mook ORF, Frederiks WM, Van Noorden CJF: The role of gelatinases in colorectal cancer progression and metastasis. (edu.iq)
  • Fernandez-Trigo V, Shamsa F, Sugarbaker PH (1995) Repeat liver resections from colorectal metastasis. (springer.com)
  • The risk of lymph node metastasis in T1 colorectal cancer: new parameters to assess the degree of submucosal invasion. (amedeo.com)
  • This is a prospective randomized trial that aimed to compare the short-term clinical outcomes and systemic inflammatory/cytokine responses of endoscopic submucosal dissection versus laparoscopic resection for early colorectal neoplasms that are not amenable to en bloc endoscopic resection with conventional techniques. (clinicaltrials.gov)
  • Laparoscopic resection represents a minimally invasive alternative for treating colorectal neoplasms that are not amenable to en bloc endoscopic resection. (clinicaltrials.gov)
  • Endoscopic submucosal dissection (ESD) is a revolutionary endoscopic procedure that enables en bloc resection of large gastrointestinal tumors, irrespective of the size of the lesion. (clinicaltrials.gov)
  • However, no report can be found in the literature comparing ESD and laparoscopic resection for early colorectal neoplasms that are not amenable to en bloc endoscopic resection with conventional techniques. (clinicaltrials.gov)
  • A potential explanation for this is that proximal neoplasms have a more subtle endoscopic appearance, making them more likely to be overlooked. (nih.gov)
  • To investigate the differences in endoscopic appearance, ie, diminutive size and nonpolypoid shape, of proximal compared with distal colorectal neoplasms. (nih.gov)
  • Of the 86 patients with advanced neoplasms, 34 (39.5%) underwent an operation, 34 (39.5%) underwent endoscopic resection, and 18 (20.9%) underwent chemotherapy or conservative treatments. (ovid.com)
  • Endoscopic submucosal dissection (ESD) is reportedly one of the standard treatment strategies for large superficial colorectal neoplasms in Japan because of its high en bloc resection rate. (elsevier.com)
  • Classification of colorectal neoplasms during colonoscopic examination is important to avoid unnecessary endoscopic biopsy or resection. (aigas.ch)
  • To reduce the risk of adverse events related to colorectal endoscopic submucosal dissection (ESD) using a conventional knife, we used a scissors-type knife (SB Knife Jr.) that allowed us to prevented unexpected muscular-layer injury. (eurekaselect.com)
  • To evaluate the usefulness of 0.4% SH as a submucosal injection solution for colorectal endoscopic resection, we conducted an open-label clinical trial on six referral hospitals in Japan. (elsevier.com)
  • A total of 41 patients with 5-20 mm neoplastic lesions localized in the colorectal mucosa at six referral hospitals in Japan in a single year period from December 2002 to November 2003 were enrolled and underwent endoscopic resection with SH. (elsevier.com)
  • The usefulness of 0.4% SH was assessed by the en bloc complete resection and the formation and maintenance of mucosal lesion-lifting during endoscopic resection. (elsevier.com)
  • Conclusion: Using 0.4% SH solution enabled sufficient lifting of a colorectal intramucosal lesion during endoscopic resection, reducing the need for additional injections and the risk of perforation. (elsevier.com)
  • Meta-analysis and systematic review of colorectal endoscopic mucosal resection. (biomedsearch.com)
  • Endoscopists at the Maastricht University Medical Center in the Netherlands who were previously trained in the detection and classification of nonpolypoid colorectal lesions. (nih.gov)
  • A total of 156 lesions were detected in the colorectum and 86 (47.8%) were diagnosed as advanced neoplasms. (ovid.com)
  • Non-polypoid colorectal lesions account for 5-36% of all colorectal cancers in Western nations and, compared to polypoid lesions, are more frequently located in the right colon, and are found in older patients. (medicinematters.com)
  • The clinical characteristics including the maximum standardized uptake value (SUVmax) were compared between advanced colorectal neoplasms and non-advanced lesions. (elsevier.com)
  • Among these 51 foci, 28 foci were judged as being advanced neoplasms, whereas 23 foci identified as non-advanced lesions. (elsevier.com)
  • The per-spot performance of PET/CT showed that SUVmax was significantly higher in advanced neoplasms than in non-advanced lesions for the early-phase (10.1±4.9 vs. 6.5±3.2, p=0.029) and the delayed-phase (12.0±6.0 vs. 7.4±4.0, p=0.022). (elsevier.com)
  • Over half of proximal neoplasms are not associated with any distal sentinel lesions. (elsevier.com)
  • They further compared family and personal histories plus environmental exposures of the carriers and noncarriers of the I1307K mutation and examined clinical differences with regard to the colorectal neoplasms and the specific molecular genetic changes in these lesions. (cdc.gov)
  • Ferrichrome reduced the progression of colorectal cancer cells derived from primary or metastatic lesions. (biomedcentral.com)
  • In the screening group , nonpolypoid lesions were more than twice as likely as polypoid lesions to contain neoplasms, whereas in the surveillance and symptomatic groups, they were more than three times as likely to contain neoplasms. (thefreedictionary.com)
  • Phase I/II studies have shown highly selective targeting of radio-labeled mAbA33 in patients with metastatic colorectal cancer, opening up the possibility of A33-directed therapy. (readbyqxmd.com)
  • Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. (ucy.ac.cy)
  • The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX. (clinicaltrials.gov)
  • This is an exploratory phase 1b/2, global, multicenter, single-arm, 2-part (phase 1b and 2) study of conatumumab in combination with panitumumab in patients with Metastatic Colorectal Cancer. (clinicaltrials.gov)
  • The objective for Part 1 is to identify a tolerable dose of conatumumab in combination with panitumumab based on the incidence of dose-limiting toxicities in patients with Metastatic Colorectal Cancer. (clinicaltrials.gov)
  • The objective for Part 2 is to evaluate the objective response rate stratified by Kirsten Rat Sarcoma Virus Oncogene (KRAS) status (wild-type versus mutant) in patients with Metastatic Colorectal Cancer treated with the combination of panitumumab and conatumumab (tolerable dose identified in part 1). (clinicaltrials.gov)
  • Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. (springer.com)
  • To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer. (bioportfolio.com)
  • S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase 3, non-inferiority trial. (bioportfolio.com)
  • Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment for metastatic colorectal cancer (mCRC). (bioportfolio.com)
  • Aflibercept combined with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) as second-line treatment of metastatic colorectal cancer (mCRC) significantly improved survival compared with FOLFIRI alone. (bioportfolio.com)
  • Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer. (bioportfolio.com)
  • Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). (bioportfolio.com)
  • The authors hypothesized that patients with metastatic colorectal cancer (mCRC) who had tumors with low thymidylate synthase (TS-L) expression would have a higher response rate to combined 5-fluoroura. (bioportfolio.com)
  • Carriers of the I1307K mutation did not appear to differ from noncarriers with regard to the number of neoplasms, patient age at detection, or tumor location within the colon. (cdc.gov)
  • Lehner B, Schlag P, Liebrich W, Schirrmacher V (1990) Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine. (springer.com)
  • Moreover, NKG2D and TCR triggering was also observed by peripheral blood derived T lymphocyte- or T cell clone-mediated tumor recognition, both in melanoma and colorectal cancer (CRC) patients. (mendeley.com)
  • We evaluated en bloc resection rate, complete resection rate, size of tumor, adverse events and local recurrence rate. (eurekaselect.com)
  • The aim of this study was to relate the density of tumor infiltrating T cells to cancer-specific survival in colorectal cancer, taking into consideration the CpG island methylator phenotype (CIMP) and microsatellite instability (MSI) screening status. (diva-portal.org)
  • Although microsatellite unstable tumor patients are generally considered to have better prognosis, we found no difference in survival between microsatellite unstable and microsatellite stable (MSS) colorectal cancer patients with similar total CD3 scores. (diva-portal.org)
  • Colorectal tumor (CRC) is the third most common malignant neoplasm worldwide. (movd2016.org)
  • The prognostic utility of the "Tumor Burden Score" based on preoperative radiographic features of colorectal liver metastases. (amedeo.com)
  • Interconnectivity between molecular subtypes and tumor stage in colorectal cancer. (amedeo.com)
  • In East Asia, stomach cancer with a relatively higher incidence rate compared to cancer in other organs shows a high rate of multiple primary cancers, and it has been reported to be associated with colorectal cancer in many cases [ 2 ]. (coloproctol.org)
  • The patient did not have any abdominal or rectal pain, or any other symptoms associated with colorectal cancer. (cancerindex.org)
  • There is considerable biologic plausibility to the hypothesis that genetic variability in pathways involved in insulin signaling and energy homeostasis may modulate dietary risk associated with colorectal cancer. (biomedsearch.com)
  • Importance of nonpolypoid (flat and depressed) colorectal neoplasms in screening for CRC in patients with IBD. (semanticscholar.org)
  • Text Reminders in Colorectal Cancer Screening (TRICCS): Protocol for a randomised controlled trial. (mhealthevidence.org)
  • BACKGROUND: Screening with the guaiac faecal occult blood test (gFOBt) is associated with improved colorectal cancer (CRC) survival, and is offered biennially to men and women aged 60-74 years in England's national Bowel Cancer Screening Programme (BCSP). (mhealthevidence.org)
  • Developing screening services for colorectal cancer on Android smartphones. (mhealthevidence.org)
  • Read more about Developing screening services for colorectal cancer on Android smartphones. (mhealthevidence.org)
  • Increasing patient/physician communications about colorectal cancer screening in rural primary care practices. (mhealthevidence.org)
  • BACKGROUND: Rural populations as well as less educated people in the United States are less likely to receive colorectal cancer (CRC) screening than people living in urban areas and more educated people. (mhealthevidence.org)
  • Small media and client reminders for colorectal cancer screening: current use and gap areas in CDC's Colorectal Cancer Control Program. (mhealthevidence.org)
  • INTRODUCTION: CDC's Colorectal Cancer Control Program (CRCCP) funds 25 states and 4 tribal organizations to promote and increase colorectal cancer screening population-wide. (mhealthevidence.org)
  • Background: Adjustment for stage at diagnosis markedly reduces USA versus European colorectal cancer survival differences and a screening bias was therefore suspected. (ucy.ac.cy)
  • Thus, the prevalence of stomach cancer and colorectal cancer is high in South Korea, and the country manages the types of cancer through the national cancer screening program. (coloproctol.org)
  • Thus, studies on the prevalence of stomach cancer and colorectal cancer in the East and the West have shown conflicting results, which is closely related with genetic and environmental factors, but there have been nearly no studies on the synchronous prevalence of stomach cancer and colorectal cancer and its screening test. (coloproctol.org)
  • We used a 6-year follow-up cohort of Taiwanese nationwide colorectal screening program with fecal immunochemical testing (FIT) to obtain fecal hemoglobin concentration and applied accelerated failure time multi-variable analyses to make the comparison of adjusted median and other percentitles of fecal hemoglobin across four categories of colorectal carcinogenesis. (biomedcentral.com)
  • Moreover, predicting the risk for colorectal neoplasia using the conventional method that treats the disease status as the outcome and f-Hb as an independent variable with adjustment for relevant factors is not appropriate for the underlying factor (such as f-Hb) that is also a part of procedure related to the confirmation of disease as seen in our population-based screening for CRC with FIT that measures f-Hb. (biomedcentral.com)
  • Our data were derived from the Taiwanese Nationwide Colorectal Cancer Screening Program, which used FIT as the screening tool. (biomedcentral.com)
  • Regarding advanced adenoma, which is the most reliable target lesion for CRC screening, several markers, including the westernization of lifestyles, obesity, and metabolic syndrome, have been reported as risk factors for this neoplasm in the younger population, especially in those aged 40-49 years. (biomedcentral.com)
  • Family history (FH) and genetic risk scores (GRSs) are increasingly used for risk stratification for colorectal cancer (CRC) screening. (nih.gov)
  • A GRS was built based on the number of risk alleles in 53 previously identified single-nucleotide polymorphisms among 2,363 patients with a first diagnosis of CRC and 2,198 controls in DACHS [colorectal cancer: chances for prevention through screening], a population-based case-control study in Germany. (nih.gov)
  • mutation screening in hereditary nonpolyposis colorectal cancer. (edu.iq)
  • Quantitation of fecal microbial DNA markers may serve as a new test, stand alone, or in combination with FIT for screening colorectal neoplasm in asymptomatic subjects. (oncologieportal.nl)
  • BACKGROUND: Limited data exist on adenoma surveillance as recommended in the European guidelines for quality assurance in colorectal cancer (CRC) screening and diagnosis after faecal occult blood test (FOBT) screening. (ku.dk)
  • 2006 In 2003, an updated review of the colorectal cancer screening and surveillance guidelines was performed by the U.S. Multisociety Task Force on Colorectal Cancer. (fascrs.org)
  • Background: There is no agreement on the best data source for measuring colorectal cancer (CRC) screening. (aacrjournals.org)
  • Colorectal cancer (CRC) screening is widely recommended for persons ages 50 and older ( 1 - 3 ). (aacrjournals.org)
  • A non-profit organization working to remove barriers to screening and to increase participation in recommended screenings for colorectal cancer and to improve screening rates. (cancerindex.org)
  • None of those in the screening group and 8% (nine patients) in the control group died of colorectal cancer. (thefreedictionary.com)
  • To review effectiveness of screening for colorectal cancer with faecal occult blood test, Hemoccult, and to consider benefits and harms of screening. (bmj.com)
  • Meta-analysis of effects of screening on mortality from colorectal cancer. (bmj.com)
  • Quality of trial design was generally high, and screening resulted in a favourable shift in the stage distribution of colorectal cancers in the screening groups. (bmj.com)
  • If a biennial Hemoccult screening programme were offered to 10 000 people and about two thirds attended for at least one Hemoccult test, 8.5 (3.6 to 13.5) deaths from colorectal cancer would be prevented over a period of 10 years. (bmj.com)
  • Although benefits of screening are likely to outweigh harms for populations at high risk of colorectal cancer, more information is needed about the harmful effects of screening, the community's responses to screening, and costs of screening for different healthcare systems before widespread screening can be recommended. (bmj.com)
  • We have reviewed the evidence about the ability of screening with the faecal occult blood test Hemoccult to reduce mortality from colorectal cancer. (bmj.com)
  • Patients ages 50 to 80 who are identified through the electronic health record as not being up to date on colorectal cancer screening are eligible for the study and will be randomly assigned to the intervention or usual care group. (knowcancer.com)
  • The proportion of patients assigned to the intervention versus usual care groups who complete a guideline recommended form of colorectal cancer screening within 4 months of the initiation of outreach will be compared. (knowcancer.com)
  • It is recommended that those affected undergo colorectal cancer screening at younger age with treatment and prevention are surgical with removal of affected tissues. (wikipedia.org)
  • 75% of all colorectal cancers have no known predisposing factors, but people who have a high-fat diet and low activity levels may be more likely than others to have this cancer. (thefreedictionary.com)
  • Studies in South Korea also have reported that the incidence of multiple primary cancers was the highest in stomach cancer [ 3 , 4 ], and a current research on the incidence of multiple primary cancers in stomach cancer patients surgically treated in South Korea found that colorectal cancer occurred most frequently [ 5 ]. (coloproctol.org)
  • Seetoo DQ, Crowe PJ, Russell PJ, Yang JL: Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. (edu.iq)
  • Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes. (amedeo.com)
  • Management of sporadic duodenal adenomas and the association with colorectal neoplasms: a retrospective cohort study. (ru.nl)
  • GOALS: To evaluate management, outcome, and follow-up of patients with sporadic duodenal adenomas and assess the presence of colorectal neoplasms. (ru.nl)
  • The team noted that metachronous neoplasm was also associated with the presence of previous or synchronous adenomas. (gastrohep.com)
  • Prevention and early detection of colorectal cancer is important. (cancerindex.org)
  • We aimed to elucidate the prevalence of colorectal neoplasm in average-risk Koreans and explore the underlying risk factors. (elsevier.com)
  • Conclusions: The overall prevalence of colorectal neoplasm in asymptomatic average-risk Koreans is comparable with that in Western countries. (elsevier.com)
  • The purpose of this study was to determine the synchronous prevalence of colorectal neoplasms in patients with stomach cancer. (coloproctol.org)
  • The results showed that the synchronous prevalence of colorectal neoplasms was higher in patients with stomach cancer than in those without stomach cancer. (coloproctol.org)
  • However, there have been only a few studies on the synchronous prevalence of stomach cancer and colorectal cancer, so more studies on its causes, mechanisms and differences by region are needed. (coloproctol.org)
  • For the synchronous prevalence of stomach cancer and colorectal cancer, while the prevalence of stomach cancer is known to be lower or similar in patients with colorectal cancer in the West [ 8 - 10 ], a higher prevalence of colorectal cancer in stomach cancer patients has been continuously reported in the East [ 11 - 13 ]. (coloproctol.org)
  • The prevalence of overall and advanced colorectal neoplasm was 20.2 and 2.5% respectively. (biomedcentral.com)
  • Advanced neoplasm was defined as adenoma of at least 10 mm, adenoma with serrated or villous component, high-grade dysplasia, and adenocarcinoma. (ovid.com)
  • Objective We investigated whether dual-time-point 18-Fluorodeoxyglucose ( 18 FDG) positron emission tomography/computed tomography (PET/CT) could improve the positive predictive value for detecting advanced colorectal neoplasms (cancer, adenoma ≥110 mm or adenoma with high-grade dysplasia). (elsevier.com)
  • Sixty-five patients with colorectal adenocarcinoma, stage I and II (TNM), undergoing curative-intent surgery and followed for five years were studied. (scielo.br)
  • They may be benign (e.g. hyperplastic polyp), pre-malignant (e.g. tubular adenoma) or malignant (e.g. colorectal adenocarcinoma). (wikipedia.org)
  • We seek to determine which of these two modes is more suitable for submucosal dissections of colorectal tumors with regard to procedure time and safety. (elsevier.com)
  • Colorectal cancer occurs when tumors form in the lining of the large intestine. (medlineplus.gov)
  • Although there has been progress in understanding the genesis of colorectal tumors, CRC-related deaths are still high, with great impact on public health programs. (scielo.br)
  • Covariate-adjusted risk stratification for multistage outcomes of colorectal neoplasia were provided by using the quantiles of fecal hemoglobin concentration, yielding the estimated life-time risks of 25th to 75th quantitles, ranging from 0.5 to 44% for colorectal cancer, 0.2 to 46% for non-advanced adenoma, and 0.1 to 20% for advanced adenoma. (biomedcentral.com)
  • Therefore, we proposed the Bayesian quantile-based survival method to first estimate covariate-adjusted f-Hb 50 and f-Hb p values and then to asses the life-time risk for the multistages of colorectal neoplasia by percentile-based f-Hb given the baseline risk of each colorectal neoplasm. (biomedcentral.com)
  • Bacteriocin production by mucosal bacteria in current and previous colorectal neoplasia. (amedeo.com)
  • It is the most common hereditary form of colorectal cancer in the United States and accounts for about 3% of all cases of cancer. (wikipedia.org)
  • The diagnosis of colorectal cancer is based on digital rectal examination, testing for blood in the stool, proctosigmoidoscopic examination of the sigmoid, and x-ray studies of the GI tract. (thefreedictionary.com)
  • Nursing care of the patient after a diagnosis of colorectal cancer focuses on coping with a possible loss of or alteration in body function. (thefreedictionary.com)
  • We have previously shown that fecal microbial markers might be useful for non?invasive diagnosis of colorectal cancer (CRC) and adenoma. (oncologieportal.nl)
  • Background/Aims: The incidence of colorectal cancer is increasing in Korea, but the epidemiology of colorectal neoplasm is not clearly defined. (elsevier.com)
  • Diet may also have an influence on the incidence of colorectal cancer, diatry fibre, retinoids, and calcium are thought to be protective, while high intake of animal fats may increases risk. (cancerindex.org)
  • Sensitivity and specificity of indocyanine green near-infrared fluorescence imaging in detection of metastatic lymph nodes in colorectal cancer: Systematic review and meta-analysis. (amedeo.com)
  • In noncolorectal, nonendocrine liver metastases, the role of surgery is less define than in colorectal or neuroendocrine cancer. (readbyqxmd.com)
  • Patients with histologically confirmed liver metastases from colorectal cancer were randomised to the vaccination or control group. (springer.com)
  • Ballantyne GH, Quin J (1993) Surgical treatment of liver metastases in patients with colorectal cancer. (springer.com)
  • de Brauw LM, van de Velde CJ, Bouwhuis-Hoogerwerf ML, Zwaveling A (1987) Diagnostic evaluation and survival analysis of colorectal cancer patients with liver metastases. (springer.com)
  • Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E (2001) Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. (springer.com)
  • Preoperative bevacizumab and volumetric recovery after resection of colorectal liver metastases. (amedeo.com)
  • Liver transplantation for unresectable colorectal liver metastases: A systematic review. (amedeo.com)
  • Influence of neoadjuvant chemotherapy on resection of primary colorectal liver metastases: A propensity score analysis. (amedeo.com)
  • Inherited syndromes (FAP, HNPCC) significantly increase the risk of colorectal cancer. (thefreedictionary.com)
  • The risk of colorectal cancer (CRC) is reduced with a low-fat, high-fibre diet. (thefreedictionary.com)
  • The aim of this study is to analyze the characteristics and risk factors of advanced colorectal neoplasm incidentally detected by 18F-FDG PET-CT. (ovid.com)
  • Patients with inflammatory bowel disease colitis have an increased risk of developing colorectal cancer compared with the general population. (semanticscholar.org)
  • Being male and older are associated with a higher risk of colorectal neoplasm. (elsevier.com)
  • See the article "Age at menarche and risk of colorectal adenoma" in volume 34 on page 998. (kjim.org)
  • 20 ] report the relationship between reproductive factors (including age at menarche) and the risk of colorectal adenoma, based on the finding that colorectal adenoma is more common in men than in women [ 21 , 22 ]. (kjim.org)
  • Although fecal hemoglobin concentration (f-Hb) was highly associated with the risk of colorectal neoplasms, current studies on this subject are hampered by skewedness of the data and the ordinal property of f-Hb has not been well studied yet. (biomedcentral.com)
  • Our aim was to develop a quantile-based method to estimate adjusted percentiles (median) of fecal hemoglobin concentration and their derived prediction for the risk of multistage outcomes of colorectal disease. (biomedcentral.com)
  • We then predicted the risk of colorectal neoplasms on the basis of the corresponding percentile values by using accelerated failure time model with Bayesian inversion method. (biomedcentral.com)
  • We aimed to identify risk factors and develop a simple prediction model for advanced colorectal neoplasm in these persons. (biomedcentral.com)
  • Older age (45-49 years), male sex, positive serology of Helicobacter pylori , and high triglyceride and low high-density lipoprotein (HDL) levels were independently associated with an increased risk of advanced colorectal neoplasm. (biomedcentral.com)
  • Older age (45-49 years), male sex, positive serology of H. pylori , high triglyceride level, and low HDL level were identified as independent risk factors for advanced colorectal neoplasm. (biomedcentral.com)
  • Therefore, the aim of this study was to identify risk factors and develop a simple prediction model for advanced colorectal neoplasm in asymptomatic individuals aged 40-49 years. (biomedcentral.com)
  • First, we identified risk factors associated with the occurrence of advanced colorectal neoplasm in the development set, and developed a simple scoring model for the prediction of advanced colorectal neoplasm based on independent risk factors. (biomedcentral.com)
  • Recent research has shown that most of the excess risk of death following breast and colorectal cancer in England compared with Norway and Sweden occurs in older age groups during the first year, and especially in the first month of follow-up. (nature.com)
  • Strongly enhanced colorectal cancer risk stratification by combining family history and genetic risk score. (nih.gov)
  • This meta-analysis examines the epidemiological evidence to characterize the association between cruciferous vegetable intake and risk of developing colorectal neoplasms. (mendeley.com)
  • The risk of developing colorectal cancer rises after age 50. (medlineplus.gov)
  • in providing staple line reinforcement and helping to reduce leaks, the study includes high risk anastomoses, defined as colorectal and coloanal anastomoses performed within 10 cm from the anal verge. (stanford.edu)
  • Adenoma patients were stratified into risk groups (low A, medium B, high C) in accordance with the European guidelines and followed up for recurrence of new neoplasms until the end of 2011. (ku.dk)
  • Risk ratios (RR) between the risk groups were calculated to assess differences in the recurrence rates of neoplasms. (ku.dk)
  • The latest issue of the Diseases of the Colon & Rectum identifies risk factors of metachronous neoplasms in colorectal cancer patients. (gastrohep.com)
  • Patients with colorectal cancer have a high risk of developing metachronous neoplasms. (gastrohep.com)
  • Dr Ballest 's team concluded, "Patients with previous or synchronous colorectal adenoma have an increased risk of developing metachronous colorectal neoplasms. (gastrohep.com)
  • Evaluate risk factors for colorectal cancer recurrence after surgical treatment. (scielo.br)
  • In this series, the factors associated with risk of colorectal cancer recurrence were the presence of lymphatic and venous vascular infiltration. (scielo.br)
  • Cumulative risk for incident and fatal colorectal cancer after polypectomy. (amedeo.com)
  • Analyses show that genetic variation influences risk of colorectal cancer associated with diet and illustrate the importance of evaluating dietary interactions beyond the level of single SNPs or haplotypes when a biologically relevant candidate pathway is examined. (biomedsearch.com)
  • To confirm the association between female hormones and colorectal neoplasm, it is necessary to investigate the degree of exposure to female hormones and the development of colorectal neoplasm considering the age at menarche, age at menopause, oral contraceptive, and combined estrogen-progestogen menopausal hormone therapy. (kjim.org)
  • Circular RNA NOX4 promotes the development of colorectal cancer via the microRNA4855p/CKS1B axis. (amedeo.com)
  • The present prospectively randomised phase III trial investigates the efficiency of active specific immunotherapy (ASI) after liver resection for hepatic metastases of colorectal cancer. (springer.com)
  • This randomized phase III study compares safety and efficacy of two sequence arms in advanced colorectal cancer: irinotecan and S-1 (IRIS) followed by oxaliplatin containing regimen (arm A. (bioportfolio.com)
  • However, if colorectal neoplasms are too large or cannot be removed 'en bloc' endoscopically, operative procedures are required to reduce risks of incomplete removal and local recurrence. (clinicaltrials.gov)
  • A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer. (amedeo.com)
  • Carbon-ion radiotherapy for isolated para-aortic lymph node recurrence from colorectal cancer. (amedeo.com)
  • Trials have shown laparoscopic colorectal surgery to be safe. (scipedia.com)
  • We also aim to explore the trend in the length of the learning curve among consultants and colorectal trainees, and determine whether or not laparoscopic colorectal surgery is amenable to surgical training. (scipedia.com)
  • All patients between July 2003 and July 2011 having laparoscopic colorectal surgery were included in a prospectively maintained database and analyzed retrospectively. (scipedia.com)
  • We conclude that laparoscopic colorectal surgery should be the standard treatment option offered to all patients regardless of age and comorbidities and it is amenable to training. (scipedia.com)
  • Laparoscopic colorectal resections. (biomedsearch.com)
  • Using homology to the rat mta1 gene, we cloned the human MTA1 gene and found it to be over-expressed in a variety of human cell lines (breast, ovarian, lung, gastric and colorectal cancer but not melanoma or sarcoma) and cancerous tissues (breast, esophageal, colorectal, gastric and pancreatic cancer). (readbyqxmd.com)
  • Sumio Fujinuma and Yoshihiro Sakai, "Study of Superficial Type Colorectal Neoplasms With Central Depression," Diagnostic and Therapeutic Endoscopy , vol. 6, no. 4, pp. 169-177, 2000. (hindawi.com)
  • The purpose of this study is to determine the efficacy and safety of bevacizumab/capecitabine/oxaliplatin combination in metastatic or recurrent Korean colorectal cancer. (bioportfolio.com)
  • Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study. (biomedsearch.com)
  • 1994) Urokinase receptor and colorectal cancer survival. (edu.iq)
  • Colorectal carcinomas (CRC) are characterised by enhanced VEGF expression and the corresponding high microvascular densities, indicating increased angiogenic activity and leading to worse patient survival. (clinicaltrials.gov)
  • Development and validation of a model to predict survival in colorectal cancer using a gradient-boosted machine. (amedeo.com)
  • Hereditary nonpolyposis colorectal cancer (HNPCC, also known as Lynch syndrome) is an hereditary colorectal cancer syndrome. (wikipedia.org)
  • Correct identification of Lynch syndrome at the time of colorectal cancer presentation is important. (centerwatch.com)
  • ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). (medlineplus.gov)
  • OBJECTIVES: To assess the frequency of Lynch Syndrome in patients with familial cancer history submitted to colorectal cancer resection. (usp.br)
  • We attempted to investigate the relationship between the presence of ACF and human colorectal carcinogenesis using a relatively large sample size. (aacrjournals.org)
  • These results suggested that ACF may serve as a reliable surrogate biomarker for human colorectal carcinogenesis. (aacrjournals.org)
  • Plasminogen activators in human colorectal neoplasms. (springer.com)
  • The clinical significance of a distal colorectal polyp is uncertain. (nih.gov)
  • Active specific immunotherapy in unselected colorectal cancer patients was not effective for prevention of recurrent metastatic disease. (springer.com)
  • A factsheet about colorectal cancer in the past, today, and how current research may change treatment and prevention in the future. (cancerindex.org)
  • We report a case of intraductal papillary mucinous neoplasm (IPMN) originating from the ileal heterotopic pancreas in a patient with hereditary non-polyposis colorectal cancer (HNPCC). (wjgnet.com)
  • ESD, which was pioneered in Japan for the treatment of early gastric neoplasms, has now been successfully applied to the colon and rectum. (clinicaltrials.gov)
  • large intestine) and rectum, which are collectively referred to as colorectal cancer. (medlineplus.gov)
  • A colorectal polyp is a polyp (fleshy growth) occurring on the lining of the colon or rectum. (wikipedia.org)
  • The expression of Shh in colon neoplasms and paired normal colonic mucosa was therefore investigated. (bvsalud.org)
  • Hedgehog signaling is likely to be associated with early tumorigenesis in colonic neoplasms . (bvsalud.org)
  • Dysregulation of the hedgehog pathway has been implicated in regeneration and carcinogenesis , leading to the expression of the sonic hedgehog (Shh) protein in gastrointestinal neoplasms . (bvsalud.org)
  • Aims - To study the involvement of uPAR in colorectal carcinogenesis. (edu.iq)